CN103641906A - 葡萄糖依赖性促胰岛素多肽类似物 - Google Patents
葡萄糖依赖性促胰岛素多肽类似物 Download PDFInfo
- Publication number
- CN103641906A CN103641906A CN201310541056.3A CN201310541056A CN103641906A CN 103641906 A CN103641906 A CN 103641906A CN 201310541056 A CN201310541056 A CN 201310541056A CN 103641906 A CN103641906 A CN 103641906A
- Authority
- CN
- China
- Prior art keywords
- hgip
- seq
- succinimide
- peg
- cys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 title abstract description 43
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 title abstract description 41
- 150000001875 compounds Chemical class 0.000 claims abstract description 70
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 239000000018 receptor agonist Substances 0.000 claims abstract description 3
- 229940044601 receptor agonist Drugs 0.000 claims abstract description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 69
- 125000000217 alkyl group Chemical group 0.000 claims description 49
- 230000008034 disappearance Effects 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 34
- -1 R 3h Chemical group 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 125000002252 acyl group Chemical group 0.000 claims description 22
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 11
- 125000000539 amino acid group Chemical group 0.000 claims description 10
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 8
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 12
- 238000011282 treatment Methods 0.000 abstract description 9
- 208000008589 Obesity Diseases 0.000 abstract description 4
- 235000020824 obesity Nutrition 0.000 abstract description 4
- 239000002464 receptor antagonist Substances 0.000 abstract description 4
- 229940044551 receptor antagonist Drugs 0.000 abstract description 4
- 230000001404 mediated effect Effects 0.000 abstract description 2
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 abstract 1
- 125000002791 glucosyl group Chemical class C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 abstract 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 120
- 229920001223 polyethylene glycol Polymers 0.000 description 88
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 63
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 46
- 108090000765 processed proteins & peptides Proteins 0.000 description 45
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 25
- 239000000203 mixture Substances 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- 239000011347 resin Substances 0.000 description 20
- 229920005989 resin Polymers 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 16
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 230000008878 coupling Effects 0.000 description 16
- 238000010168 coupling process Methods 0.000 description 16
- 238000005859 coupling reaction Methods 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 235000002639 sodium chloride Nutrition 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 11
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229910052736 halogen Inorganic materials 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 7
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- XXMYDXUIZKNHDT-QNGWXLTQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXMYDXUIZKNHDT-QNGWXLTQSA-N 0.000 description 6
- KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 description 6
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 6
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 6
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 150000003053 piperidines Chemical class 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 230000003914 insulin secretion Effects 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229920000728 polyester Polymers 0.000 description 5
- 239000012264 purified product Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 4
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 4
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 4
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 4
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 4
- 239000000859 incretin Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 3
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000003875 Wang resin Substances 0.000 description 3
- 125000002877 alkyl aryl group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000132 electrospray ionisation Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 3
- SWZCTMTWRHEBIN-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-QFIPXVFZSA-N 0.000 description 2
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 2
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 2
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 2
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 2
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical group CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AXDLCFOOGCNDST-UHFFFAOYSA-N N-Methyltyrosine Chemical compound CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 108010049869 gastric inhibitory polypeptide (1-42) Proteins 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229940047431 recombinate Drugs 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 1
- ZEQLLMOXFVKKCN-AWEZNQCLSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(OC(C)(C)C)C=C1 ZEQLLMOXFVKKCN-AWEZNQCLSA-N 0.000 description 1
- WACNXHCZHTVBJM-UHFFFAOYSA-N 1,2,3,4,5-pentafluorobenzene Chemical compound FC1=CC(F)=C(F)C(F)=C1F WACNXHCZHTVBJM-UHFFFAOYSA-N 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- AJKNNUJQFALRIK-UHFFFAOYSA-N 1,2,3-trifluorobenzene Chemical compound FC1=CC=CC(F)=C1F AJKNNUJQFALRIK-UHFFFAOYSA-N 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 description 1
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- GUOSQNAUYHMCRU-UHFFFAOYSA-N 11-Aminoundecanoic acid Chemical compound NCCCCCCCCCCC(O)=O GUOSQNAUYHMCRU-UHFFFAOYSA-N 0.000 description 1
- OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
- VNEIUVNKRDIOMW-UHFFFAOYSA-N 2-fluoro-2-(4-hydroxyphenyl)acetic acid Chemical compound OC(=O)C(F)C1=CC=C(O)C=C1 VNEIUVNKRDIOMW-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- HFXAFXVXPMUQCQ-BYPYZUCNSA-N 4-oxo-L-proline Chemical compound OC(=O)[C@@H]1CC(=O)CN1 HFXAFXVXPMUQCQ-BYPYZUCNSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- MMHCQKNDKBELOV-UHFFFAOYSA-N ClO.OC(O)C(Cl)(Cl)Cl Chemical compound ClO.OC(O)C(Cl)(Cl)Cl MMHCQKNDKBELOV-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000290 insulinogenic effect Effects 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
本发明提供了一系列新的葡萄糖依赖性促胰岛素多肽化合物的类似物,包含所述化合物的药物组合物,及所述化合物作为GIP受体激动剂或拮抗剂用于治疗GIP受体介导的疾病例如非胰岛素依赖性糖尿病和肥胖中的用途。
Description
本申请为2009年8月7日提交的、发明名称为“葡萄糖依赖性促胰岛素多肽类似物”的PCT申请PCT/US2009/004550的分案申请,所述PCT申请进入中国国家阶段的日期为2011年4月6日,申请号为200980139383.8。
发明领域
本发明涉及以下领域:葡萄糖依赖性促胰岛素多肽化合物的新类似物,包含所述化合物的药物组合物,及所述化合物作为GIP受体激动剂或拮抗剂在治疗GIP受体介导的病症例如非胰岛素依赖性糖尿病和肥胖中的用途。
技术背景
葡萄糖依赖性促胰岛素多肽(“GIP”,又称“抑胃肽”:SEQ ID NO:1)是由小肠的肠内分泌K细胞应答口服营养摄入分泌的42个残基的肽。GIP抑制胃酸的分泌,有研究显示在口服葡萄糖摄入后,GIP是胰腺β细胞分泌胰岛素的有效刺激物(“肠降血糖素效应”)(Creutzfeldt,W.,等人,1979,Diabetologia,16:75-85)。
葡萄糖和其他营养物摄入引起的胰岛素释放归因于激素和神经因子二者(Creutzfeldt,W.,等人,1985,Diabetologia,28:565-573)。已经提议了几种胃肠道调节肽作为肠降血糖素,在这些候选肽中,只有GIP和胰高血糖素样肽1(“GLP-1”)似乎满足作为餐后胰岛素释放的生理刺激物的要求(Nauck,等人,1989,J.Clin.Endorinol.Metab.,69:654-662)。有研究显示GIP和GLP-1的组合效应足以解释肠胰岛轴的完整肠降血糖素效应(Fehmann,H.C.,等人,1989,FEBS Lett.,252:109-112)。
如本领域技术人员所熟知的,GIP有多种和大量已知和潜在用途。因此,施用本发明化合物用于引发激动剂效应可具有和GIP自身相同的效应和用途。这些GIP的多种用途可总结如下:治疗疾病,所述疾病选自1型糖尿病、2型糖尿病(Visboll,T.,2004,Dan.Med.Bull.,51:364-70)、胰岛素抗性(WO2005/082928)、肥胖(Green,B.D.,等人,2004,CurrentPharmaceutical Design,10:3651-3662)、代谢紊乱(Gault,V.A.,等人,2003,Biochem.Biophys.Res.Commun.,308:207-213)、中枢神经系统疾病、神经变性疾病、充血性心力衰竭、低血糖和期望降低食物摄取和减轻体重的疾病。在胰岛中,GIP不仅急性提高胰岛素分泌,而且通过提高胰岛素原的转录和翻译刺激胰岛素的产生(Wang,等人,1996,Mol.Cell.Endocrinol.,116:81-87)并提高胰腺β细胞的生长和存活(Trumper,等人,2003,Diabetes,52:741-750)。除了作用于胰腺以提高胰岛素分泌,GIP还直接作用于胰岛素靶组织以降低血浆葡萄糖:提高脂肪(Eckel,等人,1979,Diabetes,28:1141-1142)和肌肉(O’Harte,等人,1998,J.Endocrinol.,156:237-243)中的葡萄糖摄入,并抑制肝葡萄糖产生(Elahi,D.,等人,1986,Can.J.Physiol.Pharmacol.,65:A18)。
此外,依照本发明的GIP受体拮抗剂抑制、阻断或降低动物肠内的葡萄糖吸收。依照此发现,包含GIP拮抗剂的治疗组合物可用于非胰岛素依赖性糖尿病患者以提高哺乳动物例如人对口服葡萄糖的耐受性,并通过抑制、阻断或降低哺乳动物肠内的葡萄糖吸收预防、抑制或减轻肥胖。
然而,因为未经修饰的GIP在体内约2分钟的短半衰期(Said和Mutt,1970,Science,169:1217-1218),其在治疗中的应用是受限的。在血清中,由二肽基肽酶(“DPPIV”)降解两种肠降血糖素GIP和GLP-1。提高GIP的蛋白质水解稳定性不仅保留GIP对其受体的活性,更重要的,还会避免GIP片段的产生,这些片段中的一部分起GIP受体拮抗剂的作用(Gault,等人,2002,J.Endocrinol.,175:525-533)。已报导的修饰包括对GIP N-端的保护以避免经DPPIV的蛋白质水解,所述修饰包括N-端酪氨酸的修饰(O’Harte,等人,2002,Diabetologia,45:1281-1291)、2位丙氨酸的突变(Hinke,等人,2002,Diabetes,51:656-661)、3位谷氨酸的突变(Gault,等人,2003,Biochem.Biophys.Res.Commun.,308:207-213)和13位丙氨酸的突变(Gault,等人,2003,Cell Biol.International,27:41-46)。
下面已提交的专利申请涉及GIP类似物对多种靶器官功能的效应及它们作为治疗剂的潜在用途:
PCT公开WO00/58360公开了刺激胰岛素释放的GIP肽基类似物。特别的,此申请公开了包含GIP(1-42)N-端至少15个氨基酸残基的特定肽基类似物,例如恰好包含位于1、2和3位的1个氨基酸取代或修饰的GIP类似物,例如[Pro3]GIP(1-42)。
PCT公开WO98/24464公开了基本上包含对应GIP序列7-30位的24个氨基酸多肽的GIP拮抗剂,治疗非胰岛素依赖性糖尿病的方法和提高非胰岛素依赖性糖尿病患者的葡萄糖耐受性的方法。
PCT公开WO03/082898公开了GIP的C-端截短片段和N-端修饰的类似物,以及具有减少的肽键或在靠近DPPIV特异性切割位点的氨基酸有所改变的多种GIP类似物。此申请还公开了在GIP的潜在受体结合位点间具有不同接头(linker)的类似物。(发明人)声称此申请的化合物在治疗GIP-受体介导的病症例如非胰岛素依赖性糖尿病和肥胖中有作用。
目前存在对改进的GIP类似物的需要,所述类似物在制剂中稳定,由于降低的蛋白质水解敏感性和降低的清除率在体内具有长血浆半衰期,同时保留和GIP受体的结合亲和力以引发相应的激动剂或拮抗剂效应。此外,在如此处说明的本发明化合物的其他治疗作用中,血浆葡萄糖水平的更严格控制可预防长期的糖尿病并发症,因此为患者提供了提高的生活质量。
发明概述
一方面,本发明涉及具有以下通式(I)的GIP肽变体:
(R2R3)-Tyr-Ala-Glu-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-A42-A43-R1,
(I)
其中:
A4是Gly,Acc,Aib,或β-Ala;
A5是Thr,Acc,Aib,或Ser;
A6是Phe,Acc,Aib,Aic,Cha,1Nal,2Nal,2-Pal,3-Pal,4-Pal,(X4,X5,X6,X7,X8)Phe或Trp;
A7是Ile,Abu,Acc,Aib,Ala,Cha,Leu,Nle,Phe,Tle,或Val;
A8是Ser,Aib,或Thr;
A9是Asp,Aib,或Glu;
A10是Tyr,Acc,Cha,1Nal,2Nal,2-Pal,3-Pal,4-Pal,Phe,或(X4,X5,X6,X7,X8)Phe;
A11是Ser,Acc,Aib,Nle或Thr;
A12是Ile,Abu,Acc,Aib,Ala,Cha,Leu,Nle,Phe,Tle,或Val;
A13是Ala,Acc,Aib,β-Ala,D-Ala,Gly,或Ser;
A14是Met,Abu,Acc,Aib,Ala,Cha,Ile,Leu,Nle,Phe,Tle,或Val;
A15是Asp,Aib,或Glu;
A16是Lys,Amp,Apc,Arg,hArg,Orn,HN-CH((CH2)n-N(R4R5))-C(O),Cys(琥珀酰亚胺-N-烷基),hCys(琥珀酰亚胺-N-烷基),Pen(琥珀酰亚胺-N-烷基),Cys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),hCys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Pen(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Cys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),hCys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),或Pen(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3);
A17是Ile,Abu,Acc,Aib,Ala,Cha,Leu,Nle,Phe,Tle,或Val;
A18是His,Amp,Arg,2-Pal,3-Pal,或4-Pal,Phe,或Tyr;
A19是Gln,Aib,或Asn;
A20是Gln,Aib,或Asn;
A21是Asp,Aib,或Glu;
A22是Phe,Acc,Aib,Aic,Cha,1Nal,2Nal,2-Pal,3-Pal,4-Pal,(X4,X5,X6,X7,X8)Phe,或Trp;
A23是Val,Abu,Acc,Aib,Ala,Cha,Ile,Leu,Nle,或Tle;
A24是Asn,Aib,或Gln;
A25是Trp,Acc,Aib,1Nal,2Nal,2-Pal,3-Pal,4-Pal,Phe,或(X4,X5,X6,X7,X8)Phe;
A26是Leu,Acc,Aib,Cha,Ile,Nle,Phe,(X4,X5,X6,X7,X8)Phe或Tle;
A27是Leu,Acc,Aib,Cha,Ile,Nle,Phe,(X4,X5,X6,X7,X8)Phe或Tle;
A28是Ala,Aib,或Acc;
A29是Gln,Aib,Asn,或缺失;
A30是Lys,Amp,Apc,Arg,hArg,Orn,HN-CH((CH2)n-N(R4R5))-C(O),Cys(琥珀酰亚胺-N-烷基),hCys(琥珀酰亚胺-N-烷基),Pen(琥珀酰亚胺-N-烷基),Cys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),hCys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Pen(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Cys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),hCys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),Pen(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),或缺失;
A31是Gly,Acc,Aib,β-Ala,HN-CH((CH2)n-N(R4R5))-C(O),Cys(琥珀酰亚胺-N-烷基),hCys(琥珀酰亚胺-N-烷基),Pen(琥珀酰亚胺-N-烷基),Cys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),hCys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Pen(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Cys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),hCys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),His,Pen(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),或缺失;
A32是Lys,Amp,Apc,Arg,hArg,Cys,Orn,HN-CH((CH2)n-N(R4R5))-C(O),Cys(琥珀酰亚胺-N-烷基),hCys(琥珀酰亚胺-N-烷基),Pen(琥珀酰亚胺-N-烷基),Cys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),hCys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Pen(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Cys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),hCys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),Pen(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),或缺失;
A33是Lys,Amp,Apc,Arg,hArg,Cys,Orn,HN-CH((CH2)n-N(R4R5))-C(O),Cys(琥珀酰亚胺-N-烷基),hCys(琥珀酰亚胺-N-烷基),Pen(琥珀酰亚胺-N-烷基),Cys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),hCys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Pen(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Cys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),hCys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),Pen(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),或缺失;
A34是Asn,Aib,Gln,Ser,HN-CH((CH2)n-N(R4R5))-C(O),Cys(琥珀酰亚胺-N-烷基),hCys(琥珀酰亚胺-N-烷基),Pen(琥珀酰亚胺-N-烷基),Cys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),hCys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Pen(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Cys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),hCys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),Pen(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),或缺失;
A35是Asp,Aib,Glu,HN-CH((CH2)n-N(R4R5))-C(O),Cys(琥珀酰亚胺-N-烷基),hCys(琥珀酰亚胺-N-烷基),Pen(琥珀酰亚胺-N-烷基),Cys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),hCys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Pen(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Cys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),hCys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),Pen(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),或缺失;
A36是Trp,Acc,Aib,1Nal,2Nal,2-Pal,3-Pal,4-Pal,Phe,(X4,X5,X6,X7,X8)Phe,HN-CH((CH2)n-N(R4R5))-C(O),Cys(琥珀酰亚胺-N-烷基),hCys(琥珀酰亚胺-N-烷基),Pen(琥珀酰亚胺-N-烷基),Cys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),hCys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Pen(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Cys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),hCys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),Pen(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),或缺失;
A37是Lys,Amp,Apc,Arg,hArg,Orn,HN-CH((CH2)n-N(R4R5))-C(O),Cys(琥珀酰亚胺-N-烷基),hCys(琥珀酰亚胺-N-烷基),Pen(琥珀酰亚胺-N-烷基),Cys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),hCys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Pen(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Cys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),hCys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),Pen(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),或缺失;
A38是His,Amp,2-Pal,3-Pal,4-Pal,Phe,Tyr,HN-CH((CH2)n-N(R4R5))-C(O),Cys(琥珀酰亚胺-N-烷基),hCys(琥珀酰亚胺-N-烷基),Pen(琥珀酰亚胺-N-烷基),Cys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),hCys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Pen(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Cys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),hCys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),Pen(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),或缺失;
A39是Asn,Aib,Gln,HN-CH((CH2)n-N(R4R5))-C(O),Cys(琥珀酰亚胺-N-烷基),hCys(琥珀酰亚胺-N-烷基),Pen(琥珀酰亚胺-N-烷基),Cys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),hCys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Pen(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Cys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),hCys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),Pen(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),或缺失;
A40是Ile,Acc,Aib,Ser,Thr,HN-CH((CH2)n-N(R4R5))-C(O),Cys(琥珀酰亚胺-N-烷基),hCys(琥珀酰亚胺-N-烷基),Pen(琥珀酰亚胺-N-烷基),Cys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),hCys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Pen(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Cys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),hCys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),Pen(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),或缺失;
A41是Thr,Aib,Acc,Asn,Gln,HN-CH((CH2)n-N(R4R5))-C(O),Cys(琥珀酰亚胺-N-烷基),hCys(琥珀酰亚胺-N-烷基),Pen(琥珀酰亚胺-N-烷基),Cys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),hCys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Pen(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Cys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),hCys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),Pen(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),或缺失;
A42是Gln,Acc,Aib,Asn,HN-CH((CH2)n-N(R4R5))-C(O),Cys(琥珀酰亚胺-N-烷基),hCys(琥珀酰亚胺-N-烷基),Pen(琥珀酰亚胺-N-烷基),Cys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),hCys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Pen(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Cys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),hCys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),Pen(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),或缺失;
A43是Acc,Ado,Aib,Ala,Asn,Asp,Cys,Gln,His,Phe,Thr,Trp,HN-CH((CH2)n-N(R4R5))-C(O),Cys(琥珀酰亚胺-N-烷基),hCys(琥珀酰亚胺-N-烷基),Pen(琥珀酰亚胺-N-烷基),Cys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),hCys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Pen(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3),Cys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),hCys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),Pen(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3),或缺失;
R1是OH,NH2,(C1-C30)烷氧基,或NH-X2-CH2-Z0,其中X2是(C0-C30)烃基,Z0是H,OH,CO2H,或CONH2;
R2,R3,R4和R5各独立选自H,(C1-C30)烷基,(C1-C30)杂烷基,(C1-C30)酰基,(C2-C30)烯基,(C2-C30)炔基,芳基(C1-C30)烷基,芳基(C1-C30)酰基,取代的(C1-C30)烷基,取代的(C1-C30)杂烷基,取代的(C1-C30)酰基,取代的(C2-C30)烯基,取代的(C2-C30)炔基,取代的芳基(C1-C30)烷基,和取代的芳基(C1-C30)酰基;假设R2是(C1-C30)酰基,芳基(C1-C30)酰基,取代的(C1-C30)酰基,或取代的芳基(C1-C30)酰基,则R3是H,(C1-C30)烷基,(C1-C30)杂烷基,(C2-C30)烯基,(C2-C30)炔基,芳基(C1-C30)烷基,取代的(C1-C30)烷基,取代的(C1-C30)杂烷基,取代的(C2-C30)烯基,取代的(C2-C30)炔基,或取代的芳基(C1-C30)烷基;进一步假设R4是(C1-C30)酰基,芳基(C1-C30)酰基,取代的(C1-C30)酰基,或取代的芳基(C1-C30)酰基,则R5是H,(C1-C30)烷基,(C1-C30)杂烷基,(C2-C30)烯基,(C2-C30)炔基,芳基(C1-C30)烷基,取代的(C1-C30)烷基,取代的(C1-C30)杂烷基,取代的(C2-C30)烯基,取代的(C2-C30)炔基,或取代的芳基(C1-C30)烷基;
n是每次出现独立(independently for each occurrence)的1至5(包括5)中的整数;
s,t,x和y分别是每次出现独立的1至30(包括30)中的整数;及
X4,X5,X6,X7和X8分别是每次出现独立的H,F,Cl,Br,I,(C1-10)烷基,取代的(C1-10)烷基,芳基,取代的芳基,OH,NH2,NO2,或CN。
上面通式(I)包含的化合物的子集(A)如下,其中:
A4是Gly;
A5是Thr;
A6是Phe;
A7是Ile或A6c;
A8是Ser;
A9是Asp;
A10是Tyr;
A11是Ser,A5c,或A6c;
A12是Ile;
A13是Ala或Aib;
A14是Met,A5c,A6c,或Nle;
A15是Asp;
A16是Lys;
A17是Ile;
A18是His;
A19是Gln;
A20是Gln;
A21是Asp;
A22是Phe;
A23是Val;
A24是Asn;
A25是Trp;
A26是Leu;
A27是Leu;
A28是Ala;
A29是Gln;
A30是Lys;
A31是Gly,His,Orn(N-C(O)-(CH2)12-CH3),或缺失;
A32是Lys,Cys,Cys(琥珀酰亚胺-N-(CH2)11-CH3),Cys(琥珀酰亚胺-N-(CH2)15-CH3),Orn(N-C(O)-(CH2)10-CH3),Orn(N-C(O)-(CH2)14-CH3),或缺失;
A33是Lys,Cys,Cys(琥珀酰亚胺-N-(CH2)11-CH3),Cys(琥珀酰亚胺-N-(CH2)15-CH3),Orn(N-C(O)-(CH2)10-CH3),或Orn(N-C(O)-(CH2)14-CH3),或缺失;
A34是Asn或缺失;
A35是Asp,Orn(N-C(O)-(CH2)12-CH3),或缺失;
A36是Trp或缺失;
A37是Lys或缺失;
A38是His或缺失;
A39是Asn或缺失;
A40是Ile,A5c,A6c,或缺失;
A41是Thr,A5c,A6c,或缺失;
A42是Gln,Cys(Psu),或缺失;
A43是Ado,Ala,Asn,Asp,Cys,Cys(琥珀酰亚胺-N-(CH2)11-CH3),Cys(琥珀酰亚胺-N-(CH2)15-CH3),His,Lys(N-C(O)-(CH2)10-CH3),Lys(N-C(O)-(CH2)14-CH3),Orn(N-C(O)-(CH2)14-CH3),Phe,Thr,Trp,或缺失;并
假设A7,A11,A13,A14,A31,A35,A40,A41和A42中至少1个不是天然GIP相应位置的氨基酸残基。
上面子集(A)的化合物的子集如下,其中:
A7是Ile;
A13是Ala或Aib;
A14是Met,A5c,A6c,或Nle;
A31是Gly;
A35是Asp;和
A42是Gln.
上面子集(A)的化合物的子集如下,其中:
A7是A6c;
A11是Ser;
A13是Ala;
A14是Met或Nle;
A31是Gly或Orn(N-C(O)-(CH2)12-CH3);
A32是Lys;
A33是Lys;
A35是Asp或Orn(N-C(O)-(CH2)12-CH3);
A40是Ile;
A41是Thr或A6c;
A42是Gln或Cys(Psu);和
A43是缺失。
通式(I)的优选化合物为:
实施例1:(A5c11,41)hGIP(1-42)-OH(SEQ ID NO:4);
实施例2:(A5c11,40)hGIP(1-42)-OH(SEQ ID NO:5);
实施例3:(A5c11,His43)hGIP(1-43)-OH(SEQ ID NO:6);
实施例4:(A5c11,Asn43)hGIP(1-43)-OH(SEQ ID NO:7);
实施例5:(Aib13,Asp43)hGIP(1-43)-NH2(SEQ ID NO:8);
实施例6:(Aib13,Nle14,A5c40)hGIP(1-42)-OH(SEQ ID NO:9);
实施例7:(Aib13,A5c40)hGIP(1-42)-OH(SEQ ID NO:10);
实施例8:(A5c11,Ala43)hGIP(1-43)-OH(SEQ ID NO:11);
实施例9:(Aib13,Nle14,Phe43)hGIP(1-43)-OH(SEQ ID NO:12);
实施例10:(A5c11,Thr43)hGIP(1-43)-OH(SEQ ID NO:13);
实施例11:(A6c11,14,41)hGIP(1-42)-OH(SEQ ID NO:14);
实施例12:(Aib13,Trp43)hGIP(1-43)-OH(SEQ ID NO:15);
实施例13:(A5c11,Ado43)hGIP(1-43)-OH(SEQ ID NO:16);
实施例14:(A6c11,14,40)hGIP(1-42)-OH(SEQ ID NO:17);
实施例15:[A6c7,Cys(Psu)42]hGIP(1-42)-OH(SEQ ID NO:18);
实施例16:(A6c7,41)hGIP(1-42)-OH(SEQ ID NO:19);
实施例17:(A6c7,41,Nle14)hGIP(1-42)-OH(SEQ ID NO:20);
实施例18:[A6c7,Orn35(N-C(O)-(CH2)12-CH3)]hGIP(1-42)-OH(SEQ IDNO:21);
实施例19:[A6c7,Orn31(N-C(O)-(CH2)12-CH3)]hGIP(1-42)-OH(SEQ IDNO:22);
实施例20:(A5c11,14,His43)hGIP(1-43)-OH(SEQ ID NO:23);
实施例21:(A5c11,Nle14,His43)hGIP(1-43)-OH(SEQ ID NO:24);
实施例22:[A5c11,Orn32(N-C(O)-(CH2)14-CH3),His43]hGIP(1-43)-OH(SEQID NO:25);
实施例23:[A5c11,Orn33(N-C(O)-(CH2)14-CH3),His43]hGIP(1-43)-OH(SEQID NO:26);
实施例24:[A5c11,Orn43(N-C(O)-(CH2)14-CH3)]hGIP(1-43)-OH(SEQ IDNO:27);
实施例25:[A5c11,Cys32(琥珀酰亚胺-N-(CH2)15-CH3),His43]hGIP(1-43)-OH(SEQ ID NO:28);
实施例26:[A5c11,Cys33(琥珀酰亚胺-N-(CH2)15-CH3),His43]hGIP(1-43)-OH(SEQ ID NO:29);
实施例27:[A5c11,Cys43(琥珀酰亚胺-N-(CH2)15-CH3)]hGIP(1-43)-OH(SEQ ID NO:30);
实施例28:(A5c11)hGIP(1-30)-NH2(SEQ ID NO:31);
实施例29:(A5c11,His31)hGIP(1-31)-NH2(SEQ ID NO:32);
实施例30:(A5c11,14)hGIP(1-30)-NH2(SEQ ID NO:33);
实施例31:(A5c11,41,Cys32)hGIP(1-42)-NH2(SEQ ID NO:34);
实施例32:(A5c11,41,Cys33)hGIP(1-42)-NH2(SEQ ID NO:35);
实施例33:(A5c11,41,Cys43)hGIP(1-43)-NH2(SEQ ID NO:36);
实施例34:[A5c11,Orn32(N-C(O)-(CH2)10-CH3),His43]hGIP(1-43)-OH(SEQ ID NO:37);
实施例35:[A5c11,Orn33(N-C(O)-(CH2)10-CH3),His43]hGIP(1-43)-OH(SEQ ID NO:38);
实施例36:[A5c11,Lys43(N-C(O)-(CH2)10-CH3)]hGIP(1-43)-OH(SEQID NO:39);
实施例37:[A5c11,Cys32(琥珀酰亚胺-N-(CH2)11-CH3),His43]hGIP(1-43)-OH(SEQ ID NO:40);
实施例38:[A5c11,Cys33(琥珀酰亚胺-N-(CH2)11-CH3),His43]hGIP(1-43)-OH(SEQ ID NO:41);
实施例39:[A5c11,Cys43(琥珀酰亚胺-N-(CH2)11-CH3)]hGIP(1-43)-OH(SEQ ID NO:42);
实施例40:[A5c11,Lys43(N-C(O)-(CH2)14-CH3)]hGIP(1-43)-OH(SEQID NO:43);
实施例41:[A5c11,Orn32(N-C(O)-(CH2)14-CH3),His43]hGIP(1-43)-OH(SEQ ID NO:44);和
实施例42:[A5c11,Orn33(N-C(O)-(CH2)14-CH3),His43]hGIP(1-43)-OH(SEQ ID NO:45).
根据本发明的另一个方面,上面总结的和在随附的权利要求书中要求的根据本发明的化合物可另外包含共价连接的PEG基,其中所述PEG基通过Cys(马来酰亚胺),hCys(马来酰亚胺),或Pen(马来酰亚胺)接头共价连接至化合物以形成Cys(琥珀酰亚胺-N-PEG),hCys(琥珀酰亚胺-N-PEG),或Pen(琥珀酰亚胺-N-PEG),其中“琥珀酰亚胺-N-PEG”为下面定义的线性或分支的。所述PEG基具有从约2,000至约80,000的平均分子量,优选的所述PEG基选自5K PEG,10K PEG,20K PEG,30K PEG,40K PEG,50K PEG,和60K PEG以形成Cys(琥珀酰亚胺-N-5K PEG),Cys(琥珀酰亚胺-N-10KPEG),Cys(琥珀酰亚胺-N-20K PEG),Cys(琥珀酰亚胺-N-30K PEG),Cys(琥珀酰亚胺-N-40K PEG),Cys(琥珀酰亚胺-N-50K PEG),Cys(琥珀酰亚胺-N-60K PEG),hCys(琥珀酰亚胺-N-5K PEG),hCys(琥珀酰亚胺-N-10K PEG),hCys(琥珀酰亚胺-N-20K PEG),hCys(琥珀酰亚胺-N-30K PEG),hCys(琥珀酰亚胺-N-40K PEG),hCys(琥珀酰亚胺-N-50K PEG),hCys(琥珀酰亚胺-N-60K PEG),Pen(琥珀酰亚胺-N-5K PEG),Pen(琥珀酰亚胺-N-10K PEG),Pen(琥珀酰亚胺-N-20K PEG),Pen(琥珀酰亚胺-N-30K PEG),Pen(琥珀酰亚胺-N-40K PEG),Pen(琥珀酰亚胺-N-50K PEG),或Pen(琥珀酰亚胺-N-60K PEG)。
PEG化发生在16,30,和31-43位的任一氨基酸残基,优选的在32,33和43位的任一氨基酸残基,其中Cys(琥珀酰亚胺-N-PEG),hCys(琥珀酰亚胺-N-PEG),或Pen(琥珀酰亚胺-N-PEG)位于任一所述氨基酸残基位置。
此外,上面的通式(I)可扩展为在A44-A47位提供PEG化位点。本发明所述PEG化化合物的C端可进行酰胺化,例如,(A5c11,41)hGIP(1-42)-NH2(SEQ ID NO:68),或其可保留为游离酸,例如,(A5c11,41)hGIP(1-42)-OH(SEQID NO:4)。
所述PEG化化合物的优选化合物为:
实施例43:[A5c11,41,Cys32(琥珀酰亚胺-N-20KPEG)]hGIP(1-42)-NH2(SEQ ID NO:46);
实施例44:[A5c11,41,Cys33(琥珀酰亚胺-N-20KPEG)]hGIP(1-42)-NH2(SEQ ID NO:47);
实施例45:[A5c11,41,Cys43(琥珀酰亚胺-N-20KPEG)]hGIP(1-43)-NH2(SEQ ID NO:48);
实施例46:[A5c11,41,Cys43(琥珀酰亚胺-N-30KPEG)]hGIP(1-43)-NH2(SEQ ID NO:49);
实施例47:[A5c11,Nle14,Cys43(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20K PEG)]hGIP(1-43)-NH2(SEQ ID NO:50);
实施例48:[A5c11,Nle14,Cys32(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:51);
实施例49:[A5c11,Nle14,Cys33(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:52);
实施例50:[A5c11,Cys43(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20K-PEG)]hGIP(1-43)-NH2(SEQ ID NO:53);
实施例51:[A5c11,Cys32(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20K-PEG)]hGIP(1-42)-NH2(SEQ ID NO:54);
实施例52:[A5c11,Cys33(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20K-PEG)]hGIP(1-42)-NH2(SEQ ID NO:55);
实施例53:[A5c11,Nle14,Cys43(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20K PEG)-CH2-20KPEG)]hGIP(1-43)-NH2(SEQ ID NO:56);
实施例54:[A5c11,Nle14,Cys32(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20K PEG)-CH2-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:57);
实施例55:[A5c11,Nle14,Cys33(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20K PEG)-CH2-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:58);
实施例56:[A5c11,Cys43(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20K PEG)-CH2-20K PEG)]hGIP(1-43)-NH2(SEQ ID NO:59);
实施例57:[A5c11,Cys32(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20K PEG)-CH2-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:60);
实施例58:[A5c11,Cys33(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20K PEG)-CH2-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:61);
实施例59:[A5c11,14,Cys43(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20K-PEG)]hGIP(1-43)-NH2(SEQ ID NO:62);
实施例60:[A5c11,14,Cys32(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20K-PEG)]hGIP(1-42)-NH2(SEQ ID NO:63);
实施例61:[A5c11,14,Cys33(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20K-PEG)]hGIP(1-42)-NH2(SEQ ID NO:64);
实施例62:[A5c11,14,Cys43(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20K PEG)-CH2-20K PEG)]hGIP(1-43)-NH2(SEQ ID NO:65);
实施例63:[A5c11,14,Cys32(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20K PEG)-CH2-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:66);和
实施例64:[A5c11,14,Cys33(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20K PEG)-CH2-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:67).
根据通式I更优选的化合物为:
实施例3:(A5c11,His43)hGIP(1-43)-OH(SEQ ID NO:6);
实施例33:(A5c11,41,Cys43)hGIP(1-43)-NH2(SEQ ID NO:36);
实施例46:[A5c11,41,Cys43(琥珀酰亚胺-N-30KPEG)]hGIP(1-43)-NH2(SEQ ID NO:49);
实施例40:[A5c11,Lys43(N-C(O)-(CH2)14-CH3)]hGIP(1-43)-OH(SEQID NO:43);
实施例1:(A5c11,41)hGIP(1-42)-OH(SEQ ID NO:4);
实施例4:(A5c11,Asn43)hGIP(1-43)-OH(SEQ ID NO:7);
实施例6:(Aib13,Nle14,A5c40)hGIP(1-42)-OH(SEQ ID NO:9);
实施例29:(A5c11,His31)hGIP(1-31)-NH2(SEQ ID NO:32);
实施例20:(A5c11,14,His43)hGIP(1-43)-OH(SEQ ID NO:23);
实施例5:(Aib13,Asp43)hGIP(1-43)-NH2(SEQ ID NO:8);
实施例2:(A5c11,40)hGIP(1-42)-OH(SEQ ID NO:5);
实施例43:[A5c11,41,Cys32(琥珀酰亚胺-N-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:46);
实施例45:[A5c11,41,Cys43(琥珀酰亚胺-N-20KPEG)]hGIP(1-43)-NH2(SEQ ID NO:48);
实施例21:(A5c11,Nle14,His43)hGIP(1-43)-OH(SEQ ID NO:24);
实施例44:[A5c11,41,Cys33(琥珀酰亚胺-N-20KPEG)]hGIP(1-42)-NH2(SEQ ID NO:47);
实施例30:(A5c11,14)hGIP(1-30)-NH2(SEQ ID NO:33);
实施例28:(A5c11)hGIP(1-30)-NH2(SEQ ID NO:31);
实施例36:[A5c11,Lys43(N-C(O)-(CH2)10-CH3)]hGIP(1-43)-OH(SEQID NO:39);
实施例31:(A5c11,41,Cys32)hGIP(1-42)-NH2(SEQ ID NO:34);
实施例32:(A5c11,41,Cys33)hGIP(1-42)-NH2(SEQ ID NO:35);
实施例12:(Aib13,Trp43)hGIP(1-43)-OH(SEQ ID NO:15);
实施例9:(Aib13,Nle14,Phe43)hGIP(1-43)-OH(SEQ ID NO:12);
实施例8:(A5c11,Ala43)hGIP(1-43)-OH(SEQ ID NO:11);和
实施例7:(Aib13,A5c40)hGIP(1-42)-OH(SEQ ID NO:10);或其可药用盐。
根据通式I更优选的化合物为:
实施例3:(A5c11,His43)hGIP(1-43)-OH(SEQ ID NO:6);
实施例33:(A5c11,41,Cys43)hGIP(1-43)-NH2(SEQ ID NO:36);
实施例46:[A5c11,41,Cys43(琥珀酰亚胺-N-30KPEG)]hGIP(1-43)-NH2(SEQ ID NO:49);和
实施例40:[A5c11,Lys43(N-C(O)-(CH2)14-CH3)]hGIP(1-43)-OH(SEQID NO:43);或其可药用盐。
根据通式I更优选的化合物为:
实施例3:(A5c11,His43)hGIP(1-43)-OH(SEQ ID NO:6);或其可药用盐。
附图简述
图1显示了实施例1-7的化合物和天然GIP对Sprague Dawley大鼠胰岛素释放的体内作用。
发明详述
本申请使用以下一般理解的缩写:
Abu:α-氨基丁酸
Acc:1-氨基-1-环(C3-C9)烷基羧酸
A3c:1-氨基-1-环丙烷羧酸
A4c:1-氨基-1-环丁烷羧酸
A5c:1-氨基-1-环戊烷羧酸
A6c:1-氨基-1-环己烷羧酸
Act:4-氨基-4-羧基四氢吡喃
Ado:12-氨基十二烷酸
Aib:α-氨基异丁酸
Aic:2-氨基茚-2-羧酸
Ala或A:丙氨酸
β-Ala:β-丙氨酸
Amp:4-氨基-苯基丙氨酸
Apc:4-氨基-4-羧基哌啶
Arg或R:精氨酸
hArg:高精氨酸
Asn或N:天冬酰胺
Asp或D:天冬氨酸
Aun:11-氨基十一酸
Ava:5-氨基戊酸
Cha:β-丙氨酸环己酯
Cys或C:半胱氨酸
Dhp:3,4-脱氢脯氨酸
Dmt:5,5-二甲基噻唑烷-4-羧酸
Gaba:γ-氨基丁酸
Gln或Q:谷氨酰胺
Glu或E:谷氨酸
Gly或G:甘氨酸
His或H:组氨酸
4Hppa:3-(4-羟苯基)丙酸
3Hyp:3-羟脯氨酸
4Hyp:4-羟脯氨酸
hPro:高脯氨酸
Ile或I:异亮氨酸
4Ktp:4-酮脯氨酸
Leu或L:亮氨酸
Lys或K:赖氨酸
Met或M:甲硫氨酸
Nle:正亮氨酸
Nme-Tyr:N-甲基-酪氨酸
1Nal或1-Nal:β-(1-萘基)丙氨酸
2Nal或2-Nal:β-(2-萘基)丙氨酸
Nle:正亮氨酸
Nva:正缬氨酸
Orn:鸟氨酸
2Pal或2-Pal:β-(2-吡啶)丙氨酸
3Pal或3-Pal:β-(3-吡啶)丙氨酸
4Pal或4-Pal:β-(4-吡啶)丙氨酸
Pen:青霉胺
Phe或F:苯丙氨酸
(3,4,5F)Phe:3,4,5-三氟苯丙氨酸
(2,3,4,5,6)Phe:2,3,4,5,6-五氟苯丙氨酸
Pro或P:脯氨酸
Psu:N-丙基琥珀酰亚胺
Ser或S:丝氨酸
Taz:β-(4-噻唑基)丙氨酸
3Thi:β-(3-噻吩基)丙氨酸
Thr或T:苏氨酸
Thz:硫代脯氨酸
Tic:四氢异喹啉-3-羧酸
Tle:叔亮氨酸
Trp或W:色氨酸
Tyr或Y:酪氨酸
Val或V:缬氨酸
此处使用的一些其他缩写定义如下:
Act:乙腈
Boc:叔丁氧羟基
BSA:牛血清白蛋白
DCM:二氯甲烷
DIPEA:二异丙基乙胺
DMF:二甲基甲酰胺
ESI:电喷射离子化
Fmoc:9-芴甲氧羰基
HBTU:苯并三唑-1-四甲基脲六氟磷酸酯(2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate)
HOBT:1-羟基苯并三唑
HPLC:高效液相色谱
IBMX:异丁基甲基黄嘌呤
LC-MS:液相色谱-质谱
Mtt:甲基三苯甲基
NMP:N-甲基吡咯烷酮
5K PEG:聚乙二醇,其可能包括其他官能团或基例如接头,并且其为如下面定义的线性或分支的,具有约5,000的平均总分子量
10K PEG:聚乙二醇,其可能包括其他官能团或基例如接头,并且其为如下面定义的线性或分支的,具有约10,000的平均总分子量
20K PEG:聚乙二醇,其可能包括其他官能团或基例如接头,并且其为如下面定义的线性或分支的,具有约20,000的平均总分子量
30K PEG:聚乙二醇,其可能包括其他官能团或基例如接头,并且其为如下面定义的线性或分支的,具有约30,000的平均总分子量
40K PEG:聚乙二醇,其可能包括其他官能团或基例如接头,并且其为如下面定义的线性或分支的,具有约40,000的平均总分子量
50K PEG:聚乙二醇,其可能包括其他官能团或基例如接头,并且其为如下面定义的线性或分支的,具有约50,000的平均总分子量
60K PEG:聚乙二醇,其可能包括其他官能团或基例如接头,并且其为如下面定义的线性或分支的,具有约60,000的平均总分子量
tBu:叔丁基
TIS:三异丙基硅烷
Trt:三苯甲基
TFA:三氟乙酸
Z:苄氧羰基
“Cys(琥珀酰亚胺-N-烷基)”的结构为:
“Orn(N-C(O)-(CH2)12-CH3)”的结构为:
“Cys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3)”的结构为:
其中,x=1-30,y=1-30。
“hCys(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3)”的结构为:
其中,x=1-30,y=1-30。
“Pen(琥珀酰亚胺-N-(CH2)x-C(O)-NH-(CH2)y-CH3)”的结构为:
其中,x=1-30,y=1-30。
“Cys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3)”的结构为:
其中,s=1-30,t=1-30。
“hCys(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3)”的结构为:
其中,s=1-30,t=1-30。
“Pen(琥珀酰亚胺-N-(CH2)s-NH-C(O)-(CH2)t-CH3)”的结构为:
其中,s=1-30,t=1-30。
“Cys(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-PEG)”的结构为:
“Cys(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(PEG)-CH2-PEG)”的结构为:
除了N-端氨基酸以外,在此公开中的所有氨基酸缩写(例如,Ala)代表结构-NH-CI(R')-CO-,其中R和R'分别独立的为氢或氨基酸侧链(例如R=CH3和R'=H表示Ala),或R和R'可连接形成环状体系。对N-端氨基酸,缩写代表结构(R2R3)N-CI(R')-CO-,其中R2和R3在上面的通式(I)中定义。
术语“(C1-C30)烃基”包括烷基、烯基和炔基,在烯基和炔基的情况下为C2-C30。
本发明的肽在此处也通过另一种格式表示,例如(A5c2)hGIP(1-42)-OH(SEQ ID NO:3),与天然序列相比取代的氨基酸位于括号内(例如,在hGIP中A5c2取代Ala2)。圆括号内的数字指肽中的氨基酸数(例如,hGIP(1-42)-OH(SEQ ID NO:1)为hGIP肽序列的1至42位氨基酸)。在hGIP(1-30)-NH2(SEQ ID NO:2)中的名称“NH2”表示肽的C-端是酰胺化的;hGIP(1-42)(SEQ ID NO:1)或hGIP(1-42)-OH(SEQ ID NO:1)表示C-端是游离酸。
人GIP(“hGIP”)的氨基酸序列为:
Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe-Val-
1 5 10 15 20
Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln.(SEQ ID NO:1)
25 30 35 40
“酰基”指R''-C(O)-,其中R''为H,烷基,取代的烷基,杂烷基,取代的杂烷基,烯基,取代的烯基,芳基,烷基芳基,或取代的烷基芳基。
“烷基”指包含1个或多个碳原子的烃基,其中如果有多个碳原子,其通过单键连接。烷基烃基可为直链或包含1个或多个分支或环状基团。
“取代的烷基”指烷基,其中烃基的1个或多个氢原子被1个或多个取代基替换,所述取代基选自卤素,(即,氟、氯、溴和碘),-OH,-CN,-SH,-NH2,-NHCH3,-NO2,C1-20卤素取代的烷基,-CF3,-OCH3,-OCF3,和(CH2)0-20-COOH。在不同的实施方案中存在1、2、3或4个取代基。(CH2)0-20-COOH的存在导致烷基酸的产生。烷基酸的示例包括或包含(CH2)0-20-COOH(包括2-降莰烷乙酸)、叔丁酸和3-环戊基丙酸。
“杂烷基”指烷基,其中烃基的1个或多个氢原子被1个或多个以下基团替换:氨基(amino)、酰氨基(amido)、-O-,-S-或羰基。在不同的实施方案中存在1或2个杂原子。
“取代的杂烷基”指杂烷基,其中杂烷基的氢原子被1个或多个取代基替换,所述取代基选自卤素,-OH,-CN,-SH,-NH2,-NHCH3,-NO2,-C1-20卤素取代的烷基,-CF3,-OCH3,-OCF3,和(CH2)0-20-COOH。在不同的实施方案中存在1、2、3或4个取代基。
“烯基”指由2个或多个碳原子组成的烃基,其中存在1个或多个碳-碳双键。烯烃基可为直链或包含1个或多个分支或环状基团。
“取代的烯基”指烯基,其中1个或多个氢原子被1个或多个取代基替换,所述取代基选自卤素,OH,-CN,-SH,-NH2,-NHCH3,-NO2,-C1-20卤素取代的烷基,-CF3,-OCH3,-OCF3,和(CH2)0-20-COOH。在不同的实施方案中存在1、2、3或4个取代基。
“芳基”指任选取代的芳香基团,所述芳香基团含有至少一个具有共轭的π电子体系的环,包含达3个共轭的或融合的环体系。芳基包括碳环芳基、杂环芳基和联芳基。优选的,芳基为5或6元环。用于杂环芳基的优选原子为1或多个硫、氧和/或氮。芳基的示例包括苯基、1-萘基、2-萘基、吲哚、喹啉、1-咪唑和9-蒽。芳基取代基选自C1-20烷基,-C1-20烷氧基,卤素,-OH,-CN,-SH,-NH2,-NO2,-C1-20卤素取代的烷基,-CF3,-OCF3,和(CH2)0-20-COOH。在不同的实施方案中芳基包含0、1、2、3或4个取代基。
“烷基芳基”指连接至“芳基”的“烷基”。
合成
此发明的肽可通过标准固相肽合成制备。见,例如Stewart,J.M.,等人,1984,Solid Phase Synthesis,Pierce Chemical Co.,第二版。如果R1是NH-X2-CH2-CONH2,即Z0=CONH2,则肽合成从偶联至Rink酰胺MBHA树脂的Fmoc-HN-X2-CH2-CONH2开始。如果R1是NH-X2-CH2-COOH,即Z0=COOH,则肽合成从偶联至Wang树脂的Fmoc-HN-X2-CH2-COOH开始。在此特定步骤中,使用2摩尔当量的Fmoc-HN-X2-COOH,HBTU和HOBt以及10摩尔当量的DIPEA。偶联时间为约8小时。
在包含A5c,A6c,和/或Aib的本发明GIP类似物的合成中,用于这些残基和紧接其后的残基的偶联时间为2小时。
上面通式的取代基R2和R3可通过本领域已知的标准方法连接至N-端氨基酸A1的游离胺。例如,烷基,例如(C1-C30)烷基,可使用还原烷基化连接。羟烷基,例如(C1-C30)羟烷基,也可使用还原烷基化连接,其中用叔丁基酯保护游离羟基。酰基,例如-C(O)X3,可通过游离酸例如-X3COOH的偶联连接至N-端氨基酸的游离胺,通过在二氯甲烷中将完整树脂和各3摩尔当量的游离酸和二异丙基碳二亚胺混合约1小时(进行此偶联)。如果游离酸包含游离羟基,例如3-氟-4-羟基苯乙酸,则应另外加入3摩尔当量HOBT进行偶联。
以下实施例描述了制备本发明肽的合成方法,所述方法是本领域技术人员所熟知的。其他方法也是本领域技术人员所公知的。提供的实施例是为了说明的目的,而无意以任何方式限制本发明的范围。
实施例15:[A6c
7
,Cys(Psu)
42
]hGIP(1-42)-OH
使用微波辅助的Fmoc化学在Liberty肽合成仪(CEM;Matthews,NC,USA)上以0.1mmole规模进行固相肽合成以组装肽。使用预上样的Fmoc-Cys(Trt)-Wang树脂(0.59mmole/g;Novabiochem,San Diego,CA,USA)生成C端酸肽。树脂(0.17g)与15ml二甲基甲酰胺(DMF)一起置于50ml圆锥管并上样至合成仪上的树脂位置。之后通过自动过程将树脂定量转移至反应容器。使用用于0.1mmole规模合成的标准Liberty合成方案。此方案包括通过用7ml20%哌啶(含有0.1M溶于DMF的1-羟基苯并三唑(HOBT))的初始处理去保护N-端Fmoc基。初始的去保护步骤使用微波功率(45瓦特,最高温度75℃)和氮气鼓泡(3秒开/7秒关)进行30秒。之后排空反应容器,进行第二次哌啶处理,除了持续3分钟以外与第一次处理相同。之后排空树脂并用DMF彻底清洗几次。之后加入保护氨基酸Fmoc-Thr(tBu)-OH(预先配制为0.2M溶于DMF的储液)(2.5ml,5当量),接着加入1.0ml0.45M(4.5当量)溶于DMF的HBTU[苯并三唑-1-四甲基脲六氟磷酸酯]。之后加入0.5ml2M(10当量)溶于NMP(N-甲基吡咯烷酮)的DIPEA(二异丙基乙胺)。使用20瓦特微波功率在最高温度75℃下和相同速率的氮气鼓泡进行5分钟偶联步骤。
在初始的偶联步骤之后排空反应容器并重复偶联一次。之后起始与循环1类似的循环2。类似的引入所有氨基酸,并在全序列中应用双偶联策略。循环1-3,19-20,25-26,和30-39包含紧接在偶联步骤后的加帽程序。通过加入7mL0.5M乙酸酐(含有0.015M溶于NMP的HOBT)和2mL2MDIPEA溶液进行加帽,使用多步骤微波方案:50瓦特功率30秒(65℃最高温度),之后30秒微波关闭,之后第二轮30秒微波打开(50瓦特),和之后再次无微波功率30秒。之后排空树脂,用DMF彻底清洗。使用以下氨基酸(Advanced Chemtech,Louisville,KY,USA):循环1:Fmoc-Thr(OtBu)-OH;循环2:Fmoc-Ile-OH;循环3:Fmoc-Asn(Trt)-OH;循环4:Fmoc-His(Trt)-OH;循环5:Fmoc-Lys(Boc)-OH;循环6:Fmoc-Trp(Boc)-OH;循环7:Fmoc-Asp(OtBu)-OH;循环8:Fmoc-Asn(Trt)-OH;循环9:Fmoc-Lys(Boc)-OH;循环10:Fmoc-Lys(Boc)-OH;循环11:Fmoc-Gly-OH;循环12:Fmoc-Lys(Boc)-OH;循环13:Fmoc-Gln(Trt)-OH;循环14:Fmoc-Ala-OH;循环15:Fmoc-Leu-OH;循环16:Fmoc-Leu-OH;循环17:Fmoc-Trp(Boc)-OH;循环18:Fmoc-Asn(Trt)-OH;循环19:Fmoc-Val-OH;循环20:Fmoc-Phe-OH;循环21:Fmoc-Asp(OtBu)-OH;循环22:Fmoc-Gln(Trt)-OH;循环23:Fmoc-Gln(Trt)-OH;循环24:Fmoc-His(Trt)-OH;循环25:Fmoc-Ile-OH;循环26:Fmoc-Lys(Boc)-OH;循环27:Fmoc-Asp(OtBu)-OH;循环28:Fmoc-Met-OH;循环29:Fmoc-Ala-OH;循环30:Fmoc-Ile-OH;循环31:Fmoc-Tyr(tBu)-Ser(psiMe,Me,Pro)-OH;循环32:Fmoc-Asp(OtBu)-OH;循环33:Fmoc-Ser(tBu)-OH;循环34:Fmoc-A6c-OH.循环35:Fmoc-Phe-OH;循环36:Fmoc-Gly-Thr(psiMe,Me,Pro)-OH;循环37:Fmoc-Glu(OtBu)-OH;循环38:Fmoc-Ala-OH;和循环39:Fmoc-Tyr(tBu)-OH。Fmoc-His(Trt)-OH的偶联方案是标准方案的略微修饰版本。在开始2分钟关闭微波率,之后4分钟打开微波(20瓦特;最高温度50℃)。在肽骨架组装结束后,用标准哌啶处理去除N-端的Fmoc基团。之后用DMF彻底清洗树脂,并转移回50ml圆锥管,使用DMF作为转移溶液。
去保护树脂,用5ml以下试剂处理切割树脂:5%TIS,2%水,5%(w/v)二硫苏糖醇(DTT),88%TFA,混合3.5小时。滤出液收集在45ml冷无水乙醚中。在冷离心机中以3500RPM离心沉淀10分钟。倾倒出乙醚,将肽重悬于新鲜的乙醚。乙醚处理共进行2次。最后1次乙醚清洗后,将肽在空气中干燥以去除残留乙醚。肽沉淀用8ml乙腈(Acn)和之后用8ml去离子水重悬,使其充分溶解。之后用质谱分析肽溶液。应用电喷射离子化的质谱鉴定出质量为4970.7道尔顿的主要产物;对应线性产物。用HPLC分析粗产物(约500mg),使用250x4.6毫米C18柱(Phenomenex;Torrance,CA,USA)和2-80%乙腈(0.1%TFA)梯度进行30分钟。之后用N-丙基马来酰亚胺(Pma)衍生粗产物以生成半胱氨酸侧链上的丙基琥珀酰亚胺(Psu)衍生物。将粗制线性肽以5mg/ml溶于水,用碳酸铵调节为pH6.5。加入5当量Pma并持续搅拌30秒。使用5当量二硫苏糖醇(DTT)淬灭过量的Pma。通过质谱分析衍生的肽溶液。质量分析鉴定出质量为5109.7道尔顿的主要产物;对应期望的Psu衍生产物。之后通过制备型HPLC纯化产物,使用与之前类似的梯度。通过HPLC(用于分析纯度,为96.60%)和质谱(5108.9道尔顿)分析纯化产物,之后冻干。冻干后,得到10.3mg纯化产物,相当于2%的产率。
实施例18:[A6c
7
,Orn
35
(N-C(O)-(CH
2
)
12
-CH
3
)]hGIP(1-42)-OH
使用微波辅助的Fmoc化学在Liberty肽合成仪(CEM;Matthews,NC,USA)上以0.1mmole规模进行固相肽合成以组装肽。使用预上样的Fmoc-Cys(Trt)-Wang树脂(0.59mmole/g;Novabiochem,San Diego,CA,USA)生成C端酸肽。树脂(0.17g)与15ml二甲基甲酰胺(DMF)一起置于50ml圆锥管并上样至合成仪上的树脂位置。之后通过自动过程将树脂定量转移至反应容器。使用用于0.1mmole规模合成的标准Liberty合成方案。此方案包括通过用7ml20%哌啶(含有0.1M溶于DMF的1-羟基苯并三唑(HOBT))的初始处理去保护N-端Fmoc基。初始的去保护步骤使用微波功率(45瓦特,最高温度75℃)和氮气鼓泡(3秒开/7秒关)进行30秒。之后排空反应容器,进行第二次哌啶处理,除了持续3分钟以外与第一次处理相同。之后排空树脂并用DMF彻底清洗几次。之后加入保护氨基酸Fmoc-Thr(tBu)-OH(预先配制为0.2M溶于DMF的储液)(2.5ml,5当量),接着加入1.0ml0.45M(4.5当量)溶于DMF的HBTU[苯并三唑-1-四甲基脲六氟磷酸酯]。之后加入0.5ml2M(10当量)溶于NMP(N-甲基吡咯烷酮)的DIPEA(二异丙基乙胺)。使用20瓦特微波功率在最高温度75℃下和相同速率的氮气鼓泡进行5分钟偶联步骤。
在初始的偶联步骤之后排空反应容器并重复偶联一次。之后起始与循环1类似的循环2。类似的引入所有氨基酸,并在全序列中应用双偶联策略。循环1-3,19-20,25-26,和30-39包含紧接在偶联步骤后的加帽程序。通过加入7mL0.5M乙酸酐(含有0.015M溶于NMP的HOBT)和2mL2MDIPEA溶液进行加帽,使用多步骤微波方案:50瓦特功率30秒(65℃最高温度),之后30秒微波关闭,之后第二轮30秒微波功率打开(50瓦特),和之后再次无微波功率30秒。之后排空树脂,用DMF彻底清洗。使用以下氨基酸(Advanced Chemtech,Louisville,KY,USA):循环1:Fmoc-Thr(tBu)-OH;循环2:Fmoc-Ile-OH;循环3:Fmoc-Asn(Trt)-OH;循环4:Fmoc-His(Trt)-OH;循环5:Fmoc-Lys(Boc)-OH;循环6:Fmoc-Trp(Boc)-OH;循环7:Fmoc-Orn(Mtt)-OH;循环8:Fmoc-Asn(Trt)-OH;循环9:Fmoc-Lys(Boc)-OH;循环10:Fmoc-Lys(Boc)-OH;循环11:Fmoc-Gly-OH;循环12:Fmoc-Lys(Boc)-OH;循环13:Fmoc-Gln(Trt)-OH;循环14:Fmoc-Ala-OH;循环15:Fmoc-Leu-OH;循环16:Fmoc-Leu-OH;循环17:Fmoc-Trp(Boc)-OH;循环18:Fmoc-Asn(Trt)-OH;循环19:Fmoc-Val-OH;循环20:Fmoc-Phe-OH;循环21:Fmoc-Asp(OtBu)-OH;循环22:Fmoc-Gln(Trt)-OH;循环23:Fmoc-Gln(Trt)-OH;循环24:Fmoc-His(Trt)-OH;循环25:Fmoc-Ile-OH;循环26:Fmoc-Lys(Boc)-OH;循环27:Fmoc-Asp(OtBu)-OH;循环28:Fmoc-Met-OH;循环29:Fmoc-Ala-OH;循环30:Fmoc-Ile-OH;循环31:Fmoc-Tyr(tBu)-Ser(psiMe,Me,Pro)-OH;循环32:Fmoc-Asp(OtBu)-OH;循环33:Fmoc-Ser(tBu)-OH;循环34:Fmoc-A6c-OH;循环35:Fmoc-Phe-OH;循环36:Fmoc-Gly-Thr(psiMe,Me,Pro)-OH;循环37:Fmoc-Glu(OtBu)-OH;循环38:Fmoc-Ala-OH;和循环39:Boc-Tyr(tBu)-OH。Fmoc-His(Trt)-OH的偶联方案是标准方案的略微修饰版本。在开始2分钟关闭微波功率,之后4分钟打开微波功率(20瓦特;最高温度50℃)。
肽骨架完成后,用12ml溶于二氯甲烷(DCM)的1%三氟乙酸(TFA)/5%三异丙基硅烷(TIS)处理5分钟,N2鼓泡速率为5秒开,10秒关。之后排空树脂,再次用溶于DCM溶液的1%TFA/5%TIS处理5分钟。此步骤总共进行7次以有效去除鸟氨酸侧链上的Mtt基。树脂用DCM彻底清洗几次,之后用标准哌啶步骤处理以中和鸟氨酸δN上的残留TFA盐。使用标准氨基酸偶联方案将肉豆蔻酸(CH3-(CH2)12-COOH;Aldrich,St.Louis,MO,USA)(预先配制为溶于DMF中的0.2M溶液)偶联至鸟氨酸侧链。之后用DMF彻底清洗树脂并转移回50ml圆锥管,使用DMF作为转移溶剂。
去保护树脂,用5ml以下试剂处理切割树脂:5%TIS,2%水,5%(w/v)二硫苏糖醇(DTT),88%TFA,混合3.5小时。滤出液收集在45ml冷无水乙醚中。在冷离心机中以3500RPM离心沉淀10分钟。倾倒出乙醚,将肽重悬于新鲜的乙醚。乙醚处理共进行2次。最后1次乙醚清洗后,将肽在空气中干燥以去除残留乙醚。肽沉淀用8ml乙腈(Acn)和之后用8ml去离子水重悬,使其充分溶解。之后用质谱分析肽溶液。应用电喷射离子化的质谱鉴定出质量为5205.1道尔顿的主要产物;对应期望的线性产物。用HPLC分析粗产物(约500mg),使用250x4.6毫米C18柱(Phenomenex;Torrance,CA,USA)和2-80%乙腈(0.1%TFA)梯度进行30分钟。分析型HPLC鉴定出50%纯度的产物。之后用装备C18柱的制备型HPLC纯化肽,使用类似的洗脱梯度。纯化产物用HPLC(用于分析纯度,为97.40%)和质谱(5204.6道尔顿)再次分析,之后冻干。冻干后,得到6.2mg的纯化产物,相当于1.2%的产率。
此处公开的PEG化GIP化合物可基本上根据描述的实施例15化合物的合成方案合成,通过使用PEG-马来酰亚胺替代实施例15中使用的N-丙基马来酰亚胺作为起始原料。
本发明的其他肽可由本领域普通技术人员使用与在上面实施例中公开的类似合成方案制备。此处示例的化合物的物理数据见表1。
表1
功能试验
A.体外的hGIP受体结合试验
如下制备用于体外受体结合试验的膜:使用Brinkman Polytron(设置6,15秒)在冰冷的50mM Tris-HCl中匀浆表达人重组GIP受体的CHO-K1克隆细胞,之后以39,000g10分钟离心2次,2次离心中间用新鲜的缓冲液重悬。用于试验,在50mM Tris-HCl,0.1mg/ml杆菌肽和0.1%BSA中与0.05nM[125I]GIP(~2200Ci/mmol)一起孵育等分试样的清洗后的膜制剂,25℃下100分钟。最终的试验体积为0.5ml。使用Brandel多头过滤器快速滤过GF/C滤膜(在0.5%聚氮丙啶中预浸泡)终止孵育。之后用5-ml等分试样的冰冷缓冲液清洗各试管和滤膜3次。特异结合定义为结合的总放射性配体减去在1000nM GIP存在下结合的放射性配体。此处示例的化合物的体外hGIP受体结合数据见表2。
B.人和大鼠血浆半衰期试验
将GIP肽(50μl1mg/ml)加入450μl血浆(人或大鼠),短暂涡旋并在37℃孵育。在不同时间例如在0,1,2,3,4,8,24,32,48,56,72小时取出50μl,与5μl甲酸和150μL乙腈在微离心管中混合,涡旋,并以10K rpm离心10分钟。将上清转移至注射小瓶并用LC-MS分析。LC-MS系统由具有ESI探针的API4000质谱仪组成。使用阳离子模式和全扫描检测。HPLC分离在Luna3μC8(2),2x30毫米柱上进行,使用90%A至90%B梯度以0.3ml/分钟流速进行10分钟。缓冲液A是1%溶于水的甲酸,缓冲液B是1%溶于乙腈的甲酸。此处示例的化合物的人和大鼠血浆半衰期数据见表2。
表2
C.环AMP刺激的测定
1x105表达人重组GIP受体的CHO-K1或RIN-5F胰岛瘤细胞接种至24-孔培养板(Corning Incorporate,Corning,NY,USA)中培养过夜。用于试验,细胞与0.55mM调节至pH7.3的IBMX(Sigma,St.Louis,MO,USA)在500μl Hanks平衡盐溶液(Sigma,St.Louis,MO,USA)中预孵育10分钟。之后以100nM浓度加入GIP或其类似物。在37℃孵育30分钟后,将板置于冰上,加入500μl冰冷的无水乙醇终止反应。收集孔内含物,以2,700g在4℃离心20分钟以去除细胞碎片。上清中的cAMP水平通过放射性免疫分析(New England Nuclear,Boston,MA,USA)测定。
D.正常大鼠体内胰岛素分泌的测定
使用体重约275-300g的雄性Sprague Dawley大鼠作为实验对象。处理前1天,在水合氯醛(chlorohydrate)作用下经颈静脉植入右心房套管。每个套管用100u/ml肝素盐水填充并束紧。在给药化合物或载体(盐水/0.25%BSA)前,禁食大鼠约18小时。试验当天,解冻等分试样的化合物,使达到室温并充分涡旋。仔细检查是否有未溶解的化合物。在注射化合物/葡萄糖前10分钟,取出500μl血样品并用等体积的肝素化盐水(10u/ml)替换。在时间0时从套管中取出500μl血样品。接下来,将载体或合适剂量的化合物注射进套管,并用葡萄糖(1g/kg)或载体溶液推进去。最后,使用500μl体积的肝素化盐水(10u/ml)将剩余的葡萄糖推进套管。在葡萄糖给药后2.5,5,10,和20分钟取出额外500μl血样品;每次之后立即团注,通过套管静脉注射500μl肝素化盐水(10u/ml)。通过离心从血样品中收集血浆,并贮存于-20℃直至进行胰岛素含量测定。
图1显示了实施例1-7的化合物和天然GIP对Sprague Dawley大鼠胰岛素释放的体内作用。在表3中总结了图1中显示的总胰岛素分泌数值。
表3
在如上述相同的实验条件下单独检测了实施例20的化合物的体内作用,在表4中总结了实施例20的化合物的总胰岛素分泌数值。
表4
施用
本发明的肽可以可药用盐的形式提供。所述盐的示例包括但不局限于与下述酸形成的盐:有机酸(例如醋酸,乳酸,马来酸,柠檬酸,苹果酸,抗坏血酸,琥珀酸,苯甲酸,甲磺酸,甲苯磺酸,或双羟萘酸),无机酸(例如盐酸、硫酸或磷酸)和聚合酸(例如单宁酸,羧甲基纤维素,聚乳酸,聚乙醇酸,或聚乳酸-乙醇酸的共聚物)。产生本发明肽盐的一般方法是本领域所熟知的并可通过盐交换标准方法获得。由此,可将本发明肽的TFA盐(所述TFA盐来自肽纯化,通过制备型HPLC,使用含有TFA的缓冲溶液洗脱)转化为另一种盐,例如通过在小量0.25N乙酸水溶液中溶解所述肽得到乙酸盐。将得到的溶液应用于半制备(semi-prep)HPLC柱(Zorbax,300SB,C-8)。按下述洗脱柱:(1)0.1N醋酸铵水溶液,0.5小时,(2)0.25N醋酸水溶液,0.5小时,和(3)以4ml/分钟流速的线性梯度(20%至100%溶液B洗脱30分钟)(溶液A为0.25N醋酸水溶液;溶液B为0.25N溶于80:20乙腈/水的醋酸)。收集含有肽的组分并冻干。
在此本发明组合物中的活性成分剂量可以变化;然而,活性成分的量必须能够获得合适的剂型。选择的剂量取决于期望的治疗效果、施用途径和治疗的持续时间。一般来说,用于此发明活性的有效剂量为1x10-7至200mg/kg/天,优选的1x10-4至100mg/kg/天范围内,其可作为单独剂量或分为多次剂量施用。
此发明的化合物可通过口服、肠胃外(例如肌肉、腹腔、静脉或皮下注射,或植入)、鼻、阴道、直肠、舌下或局部施用途径施用,并可与可药用载体配制以提供适用于各施用途径的剂型。
用于口服施用的固体剂型包括胶囊、片剂、丸剂、粉末和颗粒。在这些固体剂型中,活性化合物与至少1种惰性可药用载体例如蔗糖、乳糖或淀粉混合。按照通常做法,这些剂型还可包含除了这些惰性稀释剂以外的其他物质,例如润滑剂例如硬脂酸镁。在胶囊、片剂和丸剂的情况下,剂型还可包含缓冲剂。片剂和丸剂的制备还可包含肠溶衣。
用于口服施用的液体剂型包括但不局限于可药用的乳剂、溶液、悬浮液、糖浆、酏剂等等,其包含本领域常用的惰性稀释剂例如水。除了这些惰性稀释剂,组合物还可包括佐剂,例如湿润剂,乳化和悬浮剂,和甜味剂,调味剂和香料。
根据此发明的用于肠胃外施用的制剂包括但不局限于无菌水性或非水性溶液、悬液、乳剂等等。非水性溶剂或载体的示例包括丙二醇、聚乙二醇、植物油例如橄榄油和玉米油、明胶和可注射的有机酯例如油酸乙酯。这些剂型还可包含佐剂,例如防腐剂、湿润剂、乳化剂和分散剂。它们可通过如下方式灭菌,例如用截留细菌的滤器过滤,在组合物中加入灭菌剂,照射组合物或加热组合物。它们还可被制造为无菌固体组合物的形式,其可在使用前立即溶于无菌水或一些其他无菌可注射介质。
用于直肠或阴道施用的组合物优选的为栓剂,其可包含除了活性物质以外的赋形剂例如可可油或栓剂蜡。
用于鼻或舌下施用的组合物的制备还可包含本领域熟知的标准赋形剂。
此外,此发明的化合物可在持续释放的组合物中施用,例如在以下专利和专利申请中所描述的。美国专利号5,672,659教授了包含生物活性剂和聚酯的持续释放组合物。美国专利号5,595,760教授了包含胶状形式生物活性剂的持续释放组合物。美国专利号5,821,221教授了包含生物活性剂和壳聚糖的聚合持续释放组合物。美国专利号5,916,883教授了包含生物活性剂和环糊精的持续释放组合物。PCT公开号WO99/38536教授了包含生物活性剂的可吸收持续释放组合物。PCT公开号WO00/04916教授了用水包油方法制备包含治疗剂例如肽的微颗粒的方法。PCT公开号WO00/09166教授了包含治疗剂例如肽和磷酸聚合物的复合物。PCT公开号WO00/25826教授了包含治疗剂例如肽和具有非聚合内酯的聚合物的复合物。
除非另外定义,此处使用的所有技术和科学术语与此发明所属领域普通技术人员通常理解的意思相同。此外,所有此处提及的出版物、专利申请、专利和其他参考资料在此以其整体引入作为参考。
Claims (24)
1.通式(I)的化合物或其可药用盐,
(R2R3)-Tyr-Ala-Glu-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-A42-A43-R1,
(I)
其中:
A4是Gly;
A5是Thr;
A6是Phe;
A7是Ile或A6c;
A8是Ser;
A9是Asp;
A10是Tyr;
A11是Ser,A5c,或A6c;
A12是Ile;
A13是Ala或Aib;
A14是Met,A5c,A6c,或Nle;
A15是Asp;
A16是Lys;
A17是Ile;
A18是His;
A19是Gln;
A20是Gln;
A21是Asp;
A22是Phe;
A23是Val;
A24是Asn;
A25是Trp;
A26是Leu;
A27是Leu;
A28是Ala;
A29是Gln;
A30是Lys;
A31是Gly,His,Orn(N-C(O)-(CH2)12-CH3),或缺失;
A32是Lys,Cys,Cys(琥珀酰亚胺-N-(CH2)11-CH3),Cys(琥珀酰亚胺-N-(CH2)15-CH3),Orn(N-C(O)-(CH2)10-CH3),Orn(N-C(O)-(CH2)14-CH3),或缺失;
A33是Lys,Cys,Cys(琥珀酰亚胺-N-(CH2)11-CH3),Cys(琥珀酰亚胺-N-(CH2)15-CH3),Orn(N-C(O)-(CH2)10-CH3),或Orn(N-C(O)-(CH2)14-CH3),或缺失;
A34是Asn或缺失;
A35是Asp,Orn(N-C(O)-(CH2)12-CH3),或缺失;
A36是Trp或缺失;
A37是Lys或缺失;
A38是His或缺失;
A39是Asn或缺失;
A40是Ile,A5c,A6c,或缺失;
A41是Thr,A5c,A6c,或缺失;
A42是Gln,Cys(Psu),或缺失;
A43是Ado,Ala,Asn,Asp,Cys,Cys(琥珀酰亚胺-N-(CH2)11-CH3),Cys(琥珀酰亚胺-N-(CH2)15-CH3),His,Lys(N-C(O)-(CH2)10-CH3),Lys(N-C(O)-(CH2)14-CH3),Orn(N-C(O)-(CH2)14-CH3),Phe,Thr,Trp,或缺失;且
R1是OH,NH2,(C1-C30)烷氧基,或NH-X2-CH2-Z0,其中X2是(C0-C30)烃基,Z0是H,OH,CO2H,或CONH2;
R2和R3各独立选自H,(C1-C30)烷基,(C1-C30)杂烷基,(C1-C30)酰基,(C2-C30)烯基,(C2-C30)炔基,芳基(C1-C30)烷基,芳基(C1-C30)酰基,取代的(C1-C30)烷基,取代的(C1-C30)杂烷基,取代的(C1-C30)酰基,取代的(C2-C30)烯基,取代的(C2-C30)炔基,取代的芳基(C1-C30)烷基,和取代的芳基(C1-C30)酰基;假设R2是(C1-C30)酰基,芳基(C1-C30)酰基,取代的(C1-C30)酰基,或取代的芳基(C1-C30)酰基,则R3是H,(C1-C30)烷基,(C1-C30)杂烷基,(C2-C30)烯基,(C2-C30)炔基,芳基(C1-C30)烷基,取代的(C1-C30)烷基,取代的(C1-C30)杂烷基,取代的(C2-C30)烯基,取代的(C2-C30)炔基,或取代的芳基(C1-C30)烷基;
假设A7,A11,A13,A14,A31,A33,A35,A40,A41,A42和A43中至少1个不是天然GIP相应位置的氨基酸残基。
2.根据权利要求1的化合物或其可药用盐,其中所述化合物为:
(A5c11,41)hGIP(1-42)-OH(SEQ ID NO:4);
(A5c11,40)hGIP(1-42)-OH(SEQ ID NO:5);
(A5c11,His43)hGIP(1-43)-OH(SEQ ID NO:6);
(A5c11,Asn43)hGIP(1-43)-OH(SEQ ID NO:7);
(Aib13,Asp43)hGIP(1-43)-NH2(SEQ ID NO:8);
(Aib13,Nle14,A5c40)hGIP(1-42)-OH(SEQ ID NO:9);
(Aib13,A5c40)hGIP(1-42)-OH(SEQ ID NO:10);
(A5c11,Ala43)hGIP(1-43)-OH(SEQ ID NO:11);
(Aib13,Nle14,Phe43)hGIP(1-43)-OH(SEQ ID NO:12);
(A5c11,Thr43)hGIP(1-43)-OH(SEQ ID NO:13);
(A6c11,14,41)hGIP(1-42)-OH(SEQ ID NO:14);
(Aib13,Trp43)hGIP(1-43)-OH(SEQ ID NO:15);
(A5c11,Ado43)hGIP(1-43)-OH(SEQ ID NO:16);
(A6c11,14,40)hGIP(1-42)-OH(SEQ ID NO:17);
[A6c7,Cys(Psu)42]hGIP(1-42)-OH(SEQ ID NO:18);
(A6c7,41)hGIP(1-42)-OH(SEQ ID NO:19);
(A6c7,41,Nle14)hGIP(1-42)-OH(SEQ ID NO:20);
[A6c7,Orn35(N-C(O)-(CH2)12-CH3)]hGIP(1-42)-OH(SEQ ID NO:21);
[A6c7,Orn31(N-C(O)-(CH2)12-CH3)]hGIP(1-42)-OH(SEQ ID NO:22);
(A5c11,14,His43)hGIP(1-43)-OH(SEQ ID NO:23);
(A5c11,Nle14,His43)hGIP(1-43)-OH(SEQ ID NO:24);
[A5c11,Orn32(N-C(O)-(CH2)14-CH3),His43]hGIP(1-43)-OH(SEQ IDNO:25);
[A5c11,Orn33(N-C(O)-(CH2)14-CH3),His43]hGIP(1-43)-OH(SEQ IDNO:26);
[A5c11,Orn43(N-C(O)-(CH2)14-CH3)]hGIP(1-43)-OH(SEQ ID NO:27);
[A5c11,Cys32(琥珀酰亚胺-N-(CH2)15-CH3),His43]hGIP(1-43)-OH(SEQID NO:28);
[A5c11,Cys33(琥珀酰亚胺-N-(CH2)15-CH3),His43]hGIP(1-43)-OH(SEQID NO:29);
[A5c11,Cys43(琥珀酰亚胺-N-(CH2)15-CH3)]hGIP(1-43)-OH(SEQ IDNO:30);
(A5c11,His31)hGIP(1-31)-NH2(SEQ ID NO:32);
(A5c11,14)hGIP(1-30)-NH2(SEQ ID NO:33);
(A5c11,41,Cys32)hGIP(1-42)-NH2(SEQ ID NO:34);
(A5c11,41,Cys33)hGIP(1-42)-NH2(SEQ ID NO:35);
(A5c11,41,Cys43)hGIP(1-43)-NH2(SEQ ID NO:36);
[A5c11,Orn32(N-C(O)-(CH2)10-CH3),His43]hGIP(1-43)-OH(SEQ IDNO:37);
[A5c11,Orn33(N-C(O)-(CH2)10-CH3),His43]hGIP(1-43)-OH(SEQ IDNO:38);
[A5c11,Lys43(N-C(O)-(CH2)10-CH3)]hGIP(1-43)-OH(SEQ ID NO:39);
[A5c11,Cys32(琥珀酰亚胺-N-(CH2)11-CH3),His43]hGIP(1-43)-OH(SEQID NO:40);
[A5c11,Cys33(琥珀酰亚胺-N-(CH2)11-CH3),His43]hGIP(1-43)-OH(SEQID NO:41);
[A5c11,Cys43(琥珀酰亚胺-N-(CH2)11-CH3)]hGIP(1-43)-OH(SEQ IDNO:42);
[A5c11,Lys43(N-C(O)-(CH2)14-CH3)]hGIP(1-43)-OH(SEQIDNO:43);
[A5c11,Orn32(N-C(O)-(CH2)14-CH3),His43]hGIP(1-43)-OH(SEQ IDNO:44);或
[A5c11,Orn33(N-C(O)-(CH2)14-CH3),His43]hGIP(1-43)-OH(SEQ IDNO:45)。
3.根据权利要求2的化合物或其可药用盐,其中所述化合物为
(A5c11,41)hGIP(1-42)-OH(SEQ ID NO:4);
(A5c11,40)hGIP(1-42)-OH(SEQ ID NO:5);
(A5c11,His43)hGIP(1-43)-OH(SEQ ID NO:6);
(A5c11,Asn43)hGIP(1-43)-OH(SEQ ID NO:7);
(Aib13,Asp43)hGIP(1-43)-NH2(SEQ ID NO:8);
(Aib13,Nle14,A5c40)hGIP(1-42)-OH(SEQ ID NO:9);
(Aib13,A5c40)hGIP(1-42)-OH(SEQ ID NO:10);或
(A5c11,14,His43)hGIP(1-43)-OH(SEQ ID NO:23)。
4.根据权利要求2的化合物或其可药用盐,其中所述化合物为
(A5c11,His43)hGIP(1-43)-OH(SEQ ID NO:6);
(A5c11,41,Cys43)hGIP(1-43)-NH2(SEQ ID NO:36);或
[A5c11,Lys43(N-C(O)-(CH2)14-CH3)]hGIP(1-43)-OH(SEQ ID NO:43)。
5.根据权利要求4的化合物或其可药用盐,其中所述化合物为
(A5c11,His43)hGIP(1-43)-OH(SEQ ID NO:6)。
6.根据权利要求1的化合物或其可药用盐,其中:
A7是Ile;
A13是Ala或Aib;
A14是Met,A5c,A6c,或Nle;
A31是Gly或缺失;
A35是Asp或缺失;和
A42是Gln或缺失。
7.根据权利要求6的化合物或其可药用盐,其中所述化合物为:
(A5c11,41)hGIP(1-42)-OH(SEQ ID NO:4);
(A5c11,40)hGIP(1-42)-OH(SEQ ID NO:5);
(A5c11,His43)hGIP(1-43)-OH(SEQ ID NO:6);
(A5c11,Asn43)hGIP(1-43)-OH(SEQ ID NO:7);
(Aib13,Asp43)hGIP(1-43)-NH2(SEQ ID NO:8);
(Aib13,Nle14,A5c40)hGIP(1-42)-OH(SEQ ID NO:9);
(Aib13,A5c40)hGIP(1-42)-OH(SEQ ID NO:10);
(A5c11,Ala43)hGIP(1-43)-OH(SEQ ID NO:11);
(Aib13,Nle14,Phe43)hGIP(1-43)-OH(SEQ ID NO:12);
(A5c11,Thr43)hGIP(1-43)-OH(SEQ ID NO:13);
(A6c11,14,41)hGIP(1-42)-OH(SEQ ID NO:14);
(Aib13,Trp43)hGIP(1-43)-OH(SEQ ID NO:15);
(A5c11,Ado43)hGIP(1-43)-OH(SEQ ID NO:16);
(A6c11,14,40)hGIP(1-42)-OH(SEQ ID NO:17);
(A5c11,14,His43)hGIP(1-43)-OH(SEQ ID NO:23);
(A5c11,Nle14,His43)hGIP(1-43)-OH(SEQ ID NO:24);
[A5c11,Orn32(N-C(O)-(CH2)14-CH3),His43]hGIP(1-43)-OH(SEQ IDNO:25);
[A5c11,Orn33(N-C(O)-(CH2)14-CH3),His43]hGIP(1-43)-OH(SEQ IDNO:26);
[A5c11,Orn43(N-C(O)-(CH2)14-CH3)]hGIP(1-43)-OH(SEQ ID NO:27);
[A5c11,Cys32(琥珀酰亚胺-N-(CH2)15-CH3),His43]hGIP(1-43)-OH(SEQID NO:28);
[A5c11,Cys33(琥珀酰亚胺-N-(CH2)15-CH3),His43]hGIP(1-43)-OH(SEQID NO:29);
[A5c11,Cys43(琥珀酰亚胺-N-(CH2)15-CH3)]hGIP(1-43)-OH(SEQ IDNO:30);
(A5c11,14)hGIP(1-30)-NH2(SEQ ID NO:33);
(A5c11,41,Cys32)hGIP(1-42)-NH2(SEQ ID NO:34);
(A5c11,41,Cys33)hGIP(1-42)-NH2(SEQ ID NO:35);
(A5c11,41,Cys43)hGIP(1-43)-NH2(SEQ ID NO:36);
[A5c11,Orn32(N-C(O)-(CH2)10-CH3),His43]hGIP(1-43)-OH(SEQ IDNO:37);
[A5c11,Orn33(N-C(O)-(CH2)10-CH3),His43]hGIP(1-43)-OH(SEQ IDNO:38);
[A5c11,Lys43(N-C(O)-(CH2)10-CH3)]hGIP(1-43)-OH(SEQ ID NO:39);
[A5c11,Cys32(琥珀酰亚胺-N-(CH2)11-CH3),His43]hGIP(1-43)-OH(SEQID NO:40);
[A5c11,Cys33(琥珀酰亚胺-N-(CH2)11-CH3),His43]hGIP(1-43)-OH(SEQID NO:41);
[A5c11,Cys43(琥珀酰亚胺-N-(CH2)11-CH3)]hGIP(1-43)-OH(SEQ IDNO:42);
[A5c11,Lys43(N-C(O)-(CH2)14-CH3)]hGIP(1-43)-OH(SEQ ID NO:43);
[A5c11,Orn32(N-C(O)-(CH2)14-CH3),His43]hGIP(1-43)-OH(SEQ IDNO:44);或
[A5c11,Orn33(N-C(O)-(CH2)14-CH3),His43]hGIP(1-43)-OH(SEQ IDNO:45)。
8.根据权利要求1的化合物或其可药用盐,其中:
A7是A6c;
A11是Ser;
A13是Ala;
A14是Met或Nle;
A31是Gly或Orn(N-C(O)-(CH2)12-CH3);
A32是Lys;
A33是Lys;
A35是Asp或Orn(N-C(O)-(CH2)12-CH3);
A40是Ile;
A41是Thr或A6c;
A42是Gln或Cys(Psu);和
A43是缺失。
9.根据权利要求8的化合物或其可药用盐,其中所述化合物为:
[A6c7,Cys(Psu)42]hGIP(1-42)-OH(SEQ ID NO:18);
(A6c7,41)hGIP(1-42)-OH(SEQ ID NO:19);
(A6c7,41,Nle14)hGIP(1-42)-OH(SEQ ID NO:20);
[A6c7,Orn35(N-C(O)-(CH2)12-CH3)]hGIP(1-42)-OH(SEQ ID NO:21);或
[A6c7,Orn31(N-C(O)-(CH2)12-CH3)]hGIP(1-42)-OH(SEQ ID NO:22)。
10.根据权利要求1-9中任一项的化合物或其可药用盐,还包含共价连接的PEG基。
11.根据权利要求10的化合物或其可药用盐,其中所述PEG基通过Cys(马来酰亚胺),hCys(马来酰亚胺),或Pen(马来酰亚胺)接头连接至化合物以形成Cys(琥珀酰亚胺-N-PEG),hCys(琥珀酰亚胺-N-PEG),或Pen(琥珀酰亚胺-N-PEG)。
12.根据权利要求11的化合物或其可药用盐,其中所述PEG化发生在16,30,和31-43位的任一氨基酸残基位置,其中Cys(琥珀酰亚胺-N-PEG),hCys(琥珀酰亚胺-N-PEG),或Pen(琥珀酰亚胺-N-PEG)位于16,30,和31-43位的任一氨基酸残基。
13.根据权利要求12的化合物或其可药用盐,其中所述PEG化发生在32,33和43位的任一氨基酸残基,其中Cys(琥珀酰亚胺-N-PEG),hCys(琥珀酰亚胺-N-PEG),或Pen(琥珀酰亚胺-N-PEG)位于32,33和43位的任一氨基酸残基。
14.根据权利要求13的化合物或其可药用盐,其中所述PEG基具有从约2,000至约80,000的平均分子量。
15.根据权利要求13的化合物或其可药用盐,其中所述PEG选自5KPEG,10K PEG,20K PEG,30K PEG,40K PEG,50K PEG,和60K PEG以形成Cys(琥珀酰亚胺-N-5K PEG),Cys(琥珀酰亚胺-N-10K PEG),Cys(琥珀酰亚胺-N-20K PEG),Cys(琥珀酰亚胺-N-30K PEG),Cys(琥珀酰亚胺-N-40KPEG),Cys(琥珀酰亚胺-N-50K PEG),Cys(琥珀酰亚胺-N-60K PEG),hCys(琥珀酰亚胺-N-5K PEG),hCys(琥珀酰亚胺-N-10K PEG),hCys(琥珀酰亚胺-N-20K PEG),hCys(琥珀酰亚胺-N-30K PEG),hCys(琥珀酰亚胺-N-40K PEG),hCys(琥珀酰亚胺-N-50K PEG),hCys(琥珀酰亚胺-N-60KPEG),Pen(琥珀酰亚胺-N-5K PEG),Pen(琥珀酰亚胺-N-10K PEG),Pen(琥珀酰亚胺-N-20K PEG),Pen(琥珀酰亚胺-N-30K PEG),Pen(琥珀酰亚胺-N-40K PEG),或Pen(琥珀酰亚胺-N-50K PEG),或Pen(琥珀酰亚胺-N-60KPEG)。
16.根据权利要求11-15中任一项的化合物或其可药用盐,其中所述琥珀酰亚胺-N-PEG为线性的。
17.根据权利要求16的化合物或其可药用盐,其中所述线性琥珀酰亚胺-N-PEG为琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-PEG。
18.根据权利要求11-15中任一项的化合物或其可药用盐,其中所述琥珀酰亚胺-N-PEG为分支的。
19.根据权利要求18的化合物或其可药用盐,其中所述分支琥珀酰亚胺-N-PEG为琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(PEG)-CH2-PEG。
20.根据权利要求15-19中任一项的化合物或其可药用盐,其中所述化合物为:
[A5c11,41,Cys32(琥珀酰亚胺-N-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:46);
[A5c11,41,Cys33(琥珀酰亚胺-N-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:47);
[A5c11,41,Cys43(琥珀酰亚胺-N-20K PEG)]hGIP(1-43)-NH2(SEQ ID NO:48);
[A5c11,41,Cys43(琥珀酰亚胺-N-30K PEG)]hGIP(1-43)-NH2(SEQ ID NO:49);
[A5c11,Nle14,Cys43(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20KPEG)]hGIP(1-43)-NH2(SEQ ID NO:50);
[A5c11,Nle14,Cys32(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20KPEG)]hGIP(1-42)-NH2(SEQ ID NO:51);
[A5c11,Nle14,Cys33(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20KPEG)]hGIP(1-42)-NH2(SEQ ID NO:52);
[A5c11,Cys43(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20K-PEG)]hGIP(1-43)-NH2(SEQ ID NO:53);
[A5c11,Cys32(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20K-PEG)]hGIP(1-42)-NH2(SEQ ID NO:54);
[A5c11,Cys33(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20K-PEG)]hGIP(1-42)-NH2(SEQ ID NO:55);
[A5c11,Nle14,Cys43(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20KPEG)-CH2-20K PEG)]hGIP(1-43)-NH2(SEQ ID NO:56);
[A5c11,Nle14,Cys32(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20KPEG)-CH2-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:57);
[A5c11,Nle14,Cys33(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20KPEG)-CH2-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:58);
[A5c11,Cys43(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20KPEG)-CH2-20K PEG)]hGIP(1-43)-NH2(SEQ ID NO:59);
[A5c11,Cys32(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20KPEG)-CH2-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:60);
[A5c11,Cys33(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20KPEG)-CH2-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:61);
[A5c11,14,Cys43(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20K-PEG)]hGIP(1-43)-NH2(SEQ ID NO:62);
[A5c11,14,Cys32(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20K-PEG)]hGIP(1-42)-NH2(SEQ ID NO:63);
[A5c11,14,Cys33(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-20K-PEG)]hGIP(1-42)-NH2(SEQ ID NO:64);
[A5c11,14,Cys43(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20KPEG)-CH2-20K PEG)]hGIP(1-43)-NH2(SEQ ID NO:65);
[A5c11,14,Cys32(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20KPEG)-CH2-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:66);或
[A5c11,14,Cys33(琥珀酰亚胺-N-(CH2)2-C(O)NH-(CH2)3-O-CH2-CH(20KPEG)-CH2-20K PEG)]hGIP(1-42)-NH2(SEQ ID NO:67)。
21.根据权利要求20的化合物或其可药用盐,其中所述化合物为[A5c11, 41,Cys43(琥珀酰亚胺-N-30K PEG)]hGIP(1-43)-NH2(SEQ ID NO:49)。
22.包含有效量的权利要求1-21中任一项的化合物的药物组合物。
23.权利要求22的药物组合物,还包含可药用载体。
24.权利要求1-21中任一项的化合物在制备用于在需要的受试者中引发GIP受体激动剂效应的药物中的用途,其中对所述受试者施用治疗有效量的所述化合物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18818808P | 2008-08-07 | 2008-08-07 | |
US61/188,188 | 2008-08-07 | ||
US20061808P | 2008-12-02 | 2008-12-02 | |
US61/200,618 | 2008-12-02 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801393838A Division CN102170895A (zh) | 2008-08-07 | 2009-08-07 | 葡萄糖依赖性促胰岛素多肽类似物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103641906A true CN103641906A (zh) | 2014-03-19 |
Family
ID=41664128
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801393838A Pending CN102170895A (zh) | 2008-08-07 | 2009-08-07 | 葡萄糖依赖性促胰岛素多肽类似物 |
CN201310541056.3A Pending CN103641906A (zh) | 2008-08-07 | 2009-08-07 | 葡萄糖依赖性促胰岛素多肽类似物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801393838A Pending CN102170895A (zh) | 2008-08-07 | 2009-08-07 | 葡萄糖依赖性促胰岛素多肽类似物 |
Country Status (13)
Country | Link |
---|---|
US (2) | US9072703B2 (zh) |
EP (1) | EP2323678B1 (zh) |
JP (2) | JP2011530507A (zh) |
KR (3) | KR20130133104A (zh) |
CN (2) | CN102170895A (zh) |
AU (1) | AU2009280015B2 (zh) |
BR (1) | BRPI0917579A2 (zh) |
CA (1) | CA2732973A1 (zh) |
EA (1) | EA020005B1 (zh) |
ES (1) | ES2574835T3 (zh) |
HK (1) | HK1154790A1 (zh) |
MX (1) | MX2011001030A (zh) |
WO (1) | WO2010016938A2 (zh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9074014B2 (en) | 2008-08-07 | 2015-07-07 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
CN102170895A (zh) | 2008-08-07 | 2011-08-31 | 益普生制药股份有限公司 | 葡萄糖依赖性促胰岛素多肽类似物 |
CA2770617C (en) | 2009-08-10 | 2018-02-20 | Mark Smith | Reversible covalent linkage of functional molecules |
DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
ES2685987T3 (es) | 2014-09-05 | 2018-10-15 | University Of Copenhagen | Análogos de péptidos gip |
JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
PE20181327A1 (es) | 2015-12-23 | 2018-08-20 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1 |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
CA3064510A1 (en) | 2017-05-31 | 2018-12-06 | University Of Copenhagen | Long-acting gip peptide analogues |
KR102379958B1 (ko) | 2018-05-04 | 2022-04-01 | 노보 노르디스크 에이/에스 | Gip 유도체 및 이의 용도 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4562175A (en) | 1984-02-03 | 1985-12-31 | Ding Chang | Synthetic peptides |
DE69132708T2 (de) | 1990-09-24 | 2002-06-20 | Grace W R & Co | Therapeutische Vervendung von Peptiden mit Thrombospondin - ähnlicher Aktivität |
JPH04145099A (ja) * | 1990-10-05 | 1992-05-19 | Sanwa Kagaku Kenkyusho Co Ltd | Gip様活性を有するポリペプチド誘導体及びその用途 |
NZ250844A (en) * | 1993-04-07 | 1996-03-26 | Pfizer | Treatment of non-insulin dependant diabetes with peptides; composition |
US7091183B1 (en) * | 1996-12-03 | 2006-08-15 | Boston Medical Center Corporation | Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP) |
WO1998024464A1 (en) | 1996-12-03 | 1998-06-11 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
BR9915961A (pt) * | 1998-12-07 | 2001-08-21 | Sod Conseils Rech Applic | Análogos de glp-1 |
CN1935839B (zh) | 1998-12-07 | 2012-06-06 | 益普生制药股份有限公司 | 胰高血糖素样肽-1的类似物 |
GB0404124D0 (en) * | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
AU3441400A (en) | 1999-03-29 | 2000-10-16 | Uutech Limited | Peptide |
US20050272652A1 (en) | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
US20040048248A1 (en) | 1999-10-05 | 2004-03-11 | Prayaga Sudhirdas K. | Endozepine-like polypeptides and polynucleotides encoding same |
EP1392484B1 (en) | 2001-04-06 | 2013-06-12 | California Institute Of Technology | High throughput screening of crystalization of materials |
TWI284539B (en) * | 2001-07-30 | 2007-08-01 | Epix Pharm Inc | A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide |
US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
EP1526864A4 (en) | 2002-06-15 | 2006-11-08 | Enteromed Inc | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FAT TREATMENT DISEASE (NAFLD) BY ANTAGONISM OF THE RECEPTOR OF GLUCOSE-DEPENDENT INSULINOTROPE POLYPEPTIDE (GIP) |
AU2003283004A1 (en) | 2002-10-22 | 2004-05-13 | Waratah Pharmaceuticals, Inc. | Treatment of diabetes |
CA2509260C (en) * | 2002-12-31 | 2012-10-02 | Nektar Therapeutics Al, Corporation | Maleamic acid polymer derivatives and their bioconjugates |
CN102174102A (zh) | 2003-05-15 | 2011-09-07 | 塔夫茨大学信托人 | 肽和多肽药物的稳定类似物 |
EP1682584B1 (en) | 2003-11-13 | 2013-04-17 | Hanmi Science Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
CA2551039C (en) | 2003-12-16 | 2013-01-29 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Analogues of glp-1 |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
TWI376234B (en) | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
EP2390264A1 (en) * | 2005-02-11 | 2011-11-30 | Amylin Pharmaceuticals Inc. | GIP analog and hybrid polypeptides with selectable propperties |
CN101155828A (zh) * | 2005-02-11 | 2008-04-02 | 安米林药品公司 | Gip类似物和具有可选择性质的杂合多肽 |
WO2006121904A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
AU2006289259A1 (en) * | 2005-09-08 | 2007-03-15 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
US20090170762A1 (en) | 2005-09-08 | 2009-07-02 | Uutech Limited | Treatment of Diabetes Related Obesity |
EP1942115A4 (en) | 2005-10-26 | 2009-03-18 | Chugai Pharmaceutical Co Ltd | AGGLUTINABLE GLP-1 ANALOGUE AND PROLONGED RELEASE PHARMACEUTICAL COMPOSITION |
JP5399244B2 (ja) | 2006-08-17 | 2014-01-29 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド |
AU2009280021B2 (en) | 2008-08-07 | 2012-10-04 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal |
EP2915538A3 (en) | 2008-08-07 | 2015-10-14 | Ipsen Pharma S.A.S. | Truncated analogues of glucose-dependent insulinotropic polypeptide |
US9074014B2 (en) | 2008-08-07 | 2015-07-07 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
CN102170895A (zh) | 2008-08-07 | 2011-08-31 | 益普生制药股份有限公司 | 葡萄糖依赖性促胰岛素多肽类似物 |
-
2009
- 2009-08-07 CN CN2009801393838A patent/CN102170895A/zh active Pending
- 2009-08-07 CA CA2732973A patent/CA2732973A1/en not_active Abandoned
- 2009-08-07 KR KR1020137031536A patent/KR20130133104A/ko active Application Filing
- 2009-08-07 KR KR1020157011825A patent/KR101593155B1/ko not_active IP Right Cessation
- 2009-08-07 AU AU2009280015A patent/AU2009280015B2/en not_active Ceased
- 2009-08-07 CN CN201310541056.3A patent/CN103641906A/zh active Pending
- 2009-08-07 EP EP09805291.3A patent/EP2323678B1/en active Active
- 2009-08-07 MX MX2011001030A patent/MX2011001030A/es active IP Right Grant
- 2009-08-07 ES ES09805291.3T patent/ES2574835T3/es active Active
- 2009-08-07 BR BRPI0917579A patent/BRPI0917579A2/pt active Search and Examination
- 2009-08-07 EA EA201170303A patent/EA020005B1/ru not_active IP Right Cessation
- 2009-08-07 WO PCT/US2009/004550 patent/WO2010016938A2/en active Application Filing
- 2009-08-07 US US13/057,994 patent/US9072703B2/en not_active Expired - Fee Related
- 2009-08-07 JP JP2011522069A patent/JP2011530507A/ja active Pending
- 2009-08-07 KR KR1020117003755A patent/KR20110043688A/ko active Application Filing
-
2011
- 2011-08-26 HK HK11109040.8A patent/HK1154790A1/zh not_active IP Right Cessation
-
2013
- 2013-10-02 JP JP2013207160A patent/JP5881659B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-20 US US14/717,278 patent/US20150252093A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2009280015B2 (en) | 2012-11-08 |
JP2011530507A (ja) | 2011-12-22 |
AU2009280015A1 (en) | 2010-02-11 |
EP2323678A4 (en) | 2013-06-12 |
WO2010016938A2 (en) | 2010-02-11 |
KR20130133104A (ko) | 2013-12-05 |
EP2323678B1 (en) | 2016-03-23 |
EP2323678A2 (en) | 2011-05-25 |
EA020005B1 (ru) | 2014-07-30 |
KR101593155B1 (ko) | 2016-02-12 |
CA2732973A1 (en) | 2010-02-11 |
US9072703B2 (en) | 2015-07-07 |
KR20150056667A (ko) | 2015-05-26 |
JP2014028843A (ja) | 2014-02-13 |
WO2010016938A3 (en) | 2010-04-15 |
HK1154790A1 (zh) | 2012-05-04 |
US20110144007A1 (en) | 2011-06-16 |
US20150252093A1 (en) | 2015-09-10 |
CN102170895A (zh) | 2011-08-31 |
MX2011001030A (es) | 2011-04-26 |
ES2574835T3 (es) | 2016-06-22 |
BRPI0917579A2 (pt) | 2016-10-11 |
EA201170303A1 (ru) | 2011-10-31 |
JP5881659B2 (ja) | 2016-03-09 |
KR20110043688A (ko) | 2011-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102171244B (zh) | 糖依赖性胰岛素释放肽的类似物 | |
CN103641906A (zh) | 葡萄糖依赖性促胰岛素多肽类似物 | |
CN104231070B (zh) | N‑端修饰的葡萄糖依赖性促胰岛素多肽(gip)类似物 | |
KR101419332B1 (ko) | 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 절단형 유사체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
AD01 | Patent right deemed abandoned | ||
AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20180713 |